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Implementing a National Cancer Clinical Trials System  
for the 21st Century 
Second Workshop by the American Society of Clinical Oncology  
and Institute of Medicine 
 
INTRODUCTION 
The National Clinical Trials Network (NCTN) supported by the National Cancer Institute 
(NCI) has played an integral role in cancer research and in establishing the standard of care for 
cancer patients for more than 50 years. Formerly known as the NCI Clinical Trials Cooperative 
Group Program, the NCTN is comprised of more than 2,100 institutions and 14,000 
investigators, who enroll more than 20,000 cancer patients in clinical trials each year across the 
United States and internationally.  
Monica Bertagnolli, professor of surgery at Harvard Medical School, chair of the 
Alliance for Clinical Trials in Oncology, and chair of the Institute of Medicine (IOM) workshop 
planning committee, noted that cancer mortality in the United States is falling. Bertagnolli said 
that the NCTN has contributed substantially to this reduction in cancer mortality over its 56-year 
legacy. However, she added that “the world has changed in many, many ways, and it has become 
incredibly more complex and challenging to do the kind of work that we want to do.” At the 
same time, the promise of cancer research has never been greater, she said.  
John Mendelsohn, chair of the IOM National Cancer Policy Forum (NCPF) and director 
of the Khalifa Institute for Personalized Cancer Therapy at the University of Texas MD 
Anderson Cancer Center, opened the workshop with a brief overview of the 2010 IOM 
consensus report titled A National Cancer Clinical Trials System for the 21st Century: 
Reinvigorating the NCI Cooperative Group Program (IOM, 2010b). Recognizing the recent 
transformative advances in cancer research that necessitate modernization in how cancer clinical 
trials are run, as well as inefficiencies and other challenges impeding the national cancer clinical 
trials program, the NCI asked the IOM to develop a set of recommendations (summarized in 
Appendix B) to improve the federally funded cancer clinical trials system. These 
recommendations were published in the 2010 report. In early 2011, the NCPF and the American 
Society of Clinical Oncology (ASCO) held a workshop in which stakeholders discussed the 
changes they planned to implement in response to the IOM goals and recommendations (IOM, 
2011). 
Two years later, on February 11-12, 2013, in Washington, DC, the NCPF and ASCO re-
convened stakeholders to report on the changes they have made thus far to address the IOM 
recommendations.1 At this workshop, representatives from the NCI, the NCTN, comprehensive 
cancer centers, patient advocacy groups, the Food and Drug Administration (FDA), industry, and 
                                            
1 This workshop was organized by an independent planning committee whose role was limited to the identification 
of topics and speakers. This workshop summary was prepared by the rapporteurs as a factual summary of the 
presentations and discussions that took place at the workshop. Statements, recommendations, and opinions 
expressed are those of individual presenters and participants, are not necessarily endorsed or verified by the Institute 
of Medicine, the National Cancer Policy Forum, or the American Society of Clinical Oncology, and should not be 
construed as reflecting any group consensus. 
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other stakeholders highlighted the progress that has been made in achieving the goals for a 
reinvigorated national cancer clinical trials system. 
This report is a summary of that workshop. An overview of key accomplishments since 
2010 is shown in Box 1, and a summary of suggestions from individual participants for further 
improvements is provided in Box 2. A summary of NCI progress to date toward implementation 
of the IOM recommendations was presented by James Doroshow, director of the Division of 
Cancer Treatment and Diagnosis at the NCI, as shown in Table 1. The workshop agenda and 
statement of task can be found in Appendix A. The speakers’ biographies and presentations (as 
PDF and audio files) have been archived at http://www.iom.edu/Activities/Disease/NCPF/2013-
FEB-11.aspx.  
BOX 1 
Overview of Key Achievements Since 2010 
 
 Consolidated and integrated cooperative groups and operations 
 Substantially reduced median time to trial activation  
 Improved IT systems 
 Improved intellectual property terms for collaborative research 
 Improved processes and timelines for the two NCI central institutional review boards 
 Increased reimbursement to sites for large phase II studies and additional funding 
for select phase III trials based on complexity 
 New guidance from the FDA on data collection 
 New initiatives and resources to support the development of precision medicine 
 
 
BOX 2 
Overview of Suggestions Made by Individual Participants 
 
 Enhance and expand collaborations among stakeholders (e.g., the NCTN, the 
pharmaceutical and diagnostics industries, federal agencies, and patients) 
 Expand use of innovative trial designs 
 Develop and validate technologies for precision medicine 
 Define criteria for use of genomic and other biomarker tests 
 Adequately cover the costs of tumor profiling and re-biopsy if necessary 
 Create a centralized clearinghouse for annotated genetic profiles of patients’ tumors 
 Ensure that endpoint measurement is free of bias in trials assessing tumor response 
or progression 
 Assess quality-of-life issues in cancer clinical trials 
 Engage patients in trial design to enhance participation 
 Conduct a pilot study to assess whether reimbursing oncologists for the time it takes 
to inform patients about clinical trials increases patient accrual 
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TABLE 1 NCI Progress Toward Recommendations of the IOM Report A National Cancer Clinical Trials System for the 21st Century (2010)  
Goal 1: Improve speed and efficiency of the design, launch, and conduct of clinical trials   
Recommendation NCI Response as of February 2013 
1:  NCI should facilitate some 
consolidation of Cooperative Group 
“front office” operations by reviewing 
and ranking the Groups with defined 
metrics on a similar timetable and by 
linking funding to review scores 
 New Program with up to 4 adult and 1 pediatric Network Groups 
 Peer-review focused on overall research strategy, collaboration, and operational efficiency 
 Support for trials designed with integral molecular screening 
 Integrated translational science and Lead Academic Participating Site awards 
 Core RT/Imaging services 
 Strategic planning and trial prioritization at national level 
 Adult and pediatric Central Institutional Review Boards (IRBs); consent template 
 
2:  Require or facilitate consolidation 
of Group “back office” operations and, 
working with extramural community, 
make process improvement in the 
operational and organizational 
management of clinical trials a priority 
 
 Centralized 24/7 patient registration, regulatory support and site verification of trial 
participation by Cancer Trials Support Unit 
 Implementation of timelines for study review and development with major time savings for trial 
activation 
 Implementation of common IT data management system for trial development and conduct 
instituted for all new clinical trials activated in 2013 
3:  The U.S. Department of Health and 
Human Services (HHS) should lead a 
trans-agency effort to streamline and 
harmonize government oversight and 
regulation of cancer clinical trials  
 
 Established interagency agreement with FDA for rapid review of approved Group phase 3 
treatment trials at concept stage 
 Developed coordinated processes for development/review of trials under FDA Special Protocol 
Assessment (SPA) 
 Developed adult and pediatric NCI Central IRBs with major improvement in review timelines 
and AAHRRP accreditation 
 Working with CDRH/FDA to coordinate early review of investigational devices (biomarker 
tests) 
 
4:  NCI should take steps to facilitate 
more collaboration among the various 
stakeholders in cancer clinical trials  
 
 Harmonized all guidelines for programs engaged in the conduct of clinical trials so that the 
appropriate incentives are in place for collaboration (SPORES, Cancer Centers, Groups) 
 In collaboration with CEO Roundtable on Cancer, developed Standard Terms of Agreement for 
Research Trials (START) clauses for company and academic collaborations to speed clinical 
trial negotiations 
 Revised intellectual property (IP) option on all CTEP Cooperative Research and Development 
Agreements (CRADAs) relating to drug development; Biomarkers/Tissues—no blocking IP; 
royalty-free non-exclusive licenses 
 CRADA negotiations with pharmaceutical companies: 6 month absolute deadline 
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5:  NCI should mandate submission of 
annotated biospecimens to high- 
quality, standardized central 
biorepositories when samples are 
collected from patients in the course of 
Group trials and should implement 
new funding mechanisms and policies 
to support the management and use of 
those resources for retrospective 
correlative science 
 
 Revising RFA for U24 grants for National Specimen Banks for NCTN Groups to include 
common operating procedures for samples collected from patients Group and other NCI 
supported trials 
 Developing common process and procedures for requesting biospecimens banked from NCI 
clinical trials 
 Developing shared IT infrastructure to enhance specimen inventories 
Goal 2: Incorporate innovative science and trial design  
Recommendation NCI Response as of February 2013 
6:  Cooperative Groups should lead the 
development and assessment of 
innovative designs for clinical trials 
that evaluate cancer therapeutics and 
biomarkers (including combinations of 
therapies) 
 
 Initiated the Biomarker, Imaging, and Quality of Life (QOL) Studies Funding Program to ensure 
that critical correlative studies could be incorporated in a timely manner into phase 3 and large, 
multi-institutional phase 2 trials during the process of concept development. 
 From mid-2008 thru December 27, 2012, 24 of 88 concepts submitted incorporating integral and 
integrated BIQSFP-Funded Studies biomarker, imaging, QOL, and Cost Effectiveness Analysis 
studies have been supported for a total commitment of $30,538,091. 
7:  NCI, in cooperation with other 
agencies, should establish a consistent, 
dynamic process to oversee 
development of national unified 
standards 
 Under the auspices of Clinical and Translational Research Advisory Committee (CTAC), 
developed definitions of integral and integrated studies for biomarkers, imaging, and QOL 
investigations associated with Group trials 
 Working with the National Library of Medicine and the Association of American Cancer 
Institutes to develop the Cancer Trials Reporting Program (CTRP) database to provide accrual 
information related to all NCI-supported clinical trials with full accrual reporting to begin in 
2013 
 
8:  NCI should reevaluate its role in 
the clinical trials system 
 CTAC Strategic Planning Working Group was established to evaluate the overall effectiveness 
of studies conducted by NCTN 
 Revamped prioritization process for phase 3 and large phase 2 treatment and control trials 
through disease and modality-specific Steering Committees to ensure most important trials are 
given highest priority 
 NCI represents Institute priorities for the public program on the Steering Committees and 
facilitates implementation of prioritized clinical trials 
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Goal 3: Improve prioritization, selection, support, and completion of cancer clinical trials   
Recommendation NCI Response as of February 2013 
9:  NCI, Cooperative Groups, and 
physicians should take steps to 
increase the speed, volume, and 
diversity of patient accrual and to 
ensure high-quality performance at all 
sites participating in Group trials 
 Modernizing clinical trials IT infrastructure by implementing common clinical data 
management system to be used across NCI-supported clinical trials system 
 Enhancing trial participant diversity through support for Minority-based Community Clinical 
Oncology Programs, Patient Navigator Research Program, and other NCI programs 
 Working with patient advocates in concept development and accrual planning, along with 
Groups, Disease Steering Committees, and Patient Advocate Steering Committee 
 
10:  NCI should allocate a larger 
portion of its research portfolio to the 
Clinical Trials Cooperative Group 
Program to ensure that the Program 
has sufficient resources to achieve its 
unique mission 
 Developed targeted initiatives that have increased reimbursement to sites for patients on large 
phase 2 studies and additional funding provided for select phase 3 trials based on complexity as 
well as the funding for critical biomarker, imaging, and QOL studies 
 Changes in the funding model for the new Funding Opportunity Announcement: 
o Increased reimbursement for high-performing sites (~aimed at 40% accrual) 
o Need for additional infrastructure support with proposed budget increased to support 
better reimbursement but lower total level of accrual 
o Increase in core resources for genomic correlative studies 
 
Goal 4: Incentivize the participation of patients and physicians in clinical trials  
Recommendation NCI Response as of February 2013 
11: All stakeholders should work to 
ensure that clinical investigators have 
adequate training and mentoring, paid 
protected research time, necessary 
resources, and recognition  
 
 Created the Clinical Investigator Team Leadership Award to promote collaborative science and 
recognize outstanding clinical investigators; annual awards made since 2009 
12: Health care payment policies 
should value the care provided to 
patients in clinical trials and 
adequately compensate that care 
 
 Working with the NIH as well as across HHS Agencies and with other federal Agencies to help 
define and shape national policy on clinical trials and reimbursement a well as to educate 
patients and payers regarding the benefit of clinical trials 
 Working with FDA to facilitate incorporation of genomic tests into definitive clinical trials and 
the development of companion diagnostics 
SOURCE: Doroshow presentation (February 12, 2013). 
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IMPROVING SPEED AND EFFICIENCY OF TRIALS 
The first four consensus recommendations in Appendix B provided strategies to achieve 
the goal of improving the speed and efficiency of innovative clinical trials through 
reorganization of the system, by enhancing collaboration, and by streamlining and standardizing 
data collection and analysis. A major focus since 2010 has been on consolidating and integrating 
the participating cooperative groups and providing more centralized administrative and 
information technology (IT) support and data management to improve collaboration and 
operational efficiency. 
Reorganization of the NCTN 
The cooperative groups have reorganized themselves into four groups focused on adult 
cancers, in addition to a preexisting group focused on pediatric cancers (Box 3). This 
reorganization has been an enormous undertaking and is partly due to a new Funding 
Opportunity Announcement from the NCI that limited funding to five groups. The merged 
groups submitted proposals in response to that Announcement in February 2013, and awards are 
anticipated in 2014. Thus, the consolidation is still a work in progress. The Clinical Trials 
Strategic Planning Subcommittee, a subgroup of the NCI’s Clinical Trials and Translational 
Research Advisory Committee (CTAC), is charged with helping to develop a fully integrated 
Clinical Trials System. 
 
BOX 3 
Reconfigured Groups of the NCTN 
 
 Alliance for Clinical Trials in Oncology (consolidation of Cancer and Leukemia 
Group B, the North Central Cancer Treatment Group, and the American College of 
Surgeons Oncology Group) 
 Children’s Oncology Group 
 ECOG-ACRIN Cancer Research Group (consolidation of the Eastern Cooperative 
Oncology Group and the American College of Radiology Imaging Network) 
 NRG Oncology (consolidation of the National Surgical Adjuvant Breast and Bowel 
Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology 
Group) 
 SWOG (formerly known as Southwest Oncology Group) 
 
SOURCE: Comis presentation (February 11, 2013). 
 
However, group leaders stressed the benefits of consolidation. Bertagnolli said, “I think 
it’s very important to acknowledge the tremendous and extremely positive impact that the 
involvement of the IOM in our enterprise has had. The initial consensus statement and the first 
workshop have yielded truly amazing changes that have updated the groups and allowed us to 
really feel confident as we go forward that the work that we do will be preserved and even 
strengthened.”  
Robert Comis, president and chair of the Coalition of Cancer Cooperative Groups, group 
chair of the Eastern Cooperative Oncology Group, and professor of medicine and director of the 
Clinical Trials Research Center at Drexel University, concurred. He reported that the 
consolidation of the Eastern Cooperative Oncology Group (ECOG) with the American College 
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of Radiology Imaging Network (ACRIN) will enable an integrated data warehouse that will 
include case report forms and imaging data, digital pathology, a specimen repository inventory, 
and “omics” information and resources, adding that the pooling of resources will enable ECOG 
to take advantage of ACRIN’s tremendous amount of electronic imaging data. “From the 
inception of the ECOG-ACRIN idea, we had always envisioned this as a great opportunity, not 
just for us but for the whole system,” he said.  
NCTN group operations were also reorganized into five major hubs: 
1. Statistics and data management centers 
2. Radiation therapy and imaging core services centers 
3. Integrated translational science centers 
4. Lead academic participating sites 
5. The Canadian Collaborating Clinical Trials Network 
 
All groups will contribute to and use the resources of the newly established integrated 
translational science centers, Comis noted. The goal is to develop integrated next-generation 
sequencing, advanced imaging, immunobiology, biorepositories with clinically annotated 
specimens, and reference labs. These centers will offer a platform for sustained, cutting-edge 
scientific effort and enhance interactions across groups and with cancer centers, he stressed. 
The NCI has also expanded its Cancer Trials Support Unit to enable centralized 
administrative and regulatory functions for clinical trials. It now offers 24/7 centralized Web-
based patient registration; provides educational materials for patients, nurses, and physicians; 
and offers regulatory support, financial management, accrual reimbursement, and protocol 
coordination, as well as other types of support. 
Aggressive Timelines 
Previous studies indicated that a substantial contributor to the inefficiency of cancer 
clinical trials has been the length of time between when a trial concept is first proposed and when 
it is approved and activated, said Doroshow. Prior to 2008, it often took more than 2 years to 
activate a phase III trial and nearly that long for early-phase trials as well. However, several 
changes have substantially reduced the median time to trial activation, with a 30 percent 
improvement for early-phase trials and a 50 percent improvement for phase III trials (see Figure 
1). 
These time-saving changes include setting aggressive timelines for implementing clinical 
trials that provide not only optimal target dates, but also absolute cutoff dates, after which a trial 
cannot be activated. The NCI also established a new website that tracks all phases of a protocol’s 
life cycle, created new positions to manage protocol development, and implemented uniform 
templates for protocol development and reviewers’ comments.  
Other major contributors to the shortened trial activation time include improved 
processes for the two NCI central institutional review boards (IRBs)—one for adult and one for 
pediatric trials—and updated consent templates. These changes slashed the time from protocol 
receipt to trial approval by a central IRB from a median of about 4 to 5 months in 2008 to only 3 
weeks in 2012. As of 2013, all NCTN trials are required to use the central IRBs (with waiver 
exemptions possible for sites demonstrating similar local IRB review timelines). 
“This will decrease a lot of needless busy work that results from having hundreds of 
institutions review the same protocols,” Doroshow said. It will also facilitate more clinical trials 
of rare cancers by enabling rapid approval of a trial as patients with these rare diseases are 
encountered in the clinic, he added. “Now that we’re going to have these small and molecularly  
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FIGURE 1 Timeline comparison of trial activation, historical vs. post-implementation of the 
recommendations from the operational Efficiency Working Group, April 2010 to August 2012.  
NOTES: A = early-phase studies; B = phase III studies. LOI = letter of intent; OEWG= Operational 
Efficiency Working Group. 
SOURCE: Doroshow presentation (February 11, 2013). 
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defined populations, it’s rather critical that institutions have the ability to open trials when they 
find the right patients, because we probably will have many more trials with such small 
populations,” said Jeffrey Abrams, associate director of the Cancer Therapy Evaluation Program 
in the Division of Cancer Treatment and Diagnosis at the NCI. 
However, the time needed for acquisition of the drug being tested and approval from 
industry sponsors to begin testing it is still delaying trial activation, Doroshow noted. Despite a 
30 percent improvement in early-phase trial activation times, he said, “We have to do better in 
interacting with pharma and getting approvals for these trials in a timely manner. We have to get 
these trials open in about 6 to 7 months to be appropriately timed for what our industry partners 
expect.” 
Information Technology Improvements 
The elements of a new common IT data management system the NCI instituted for the 
NCTN have generated multiple benefits as well (see Box 4). The new Medidata Rave Web-based 
remote data entry system, initiated in April 2011, enables the user to record patient information 
using standard forms customized for each study. “The most remarkable effort has been to 
implement a uniform clinical trials management system across this network with 3,000 sites,” 
said Doroshow. “There is no country and no pharmaceutical organization that has a uniform 
clinical trials data management system that unites so many sites.” 
 
BOX 4 
Common IT Data Management System (CDMS) 
 
Electronic tool(s) or processes that support 
 Data collection: Remote Data Capture  
 Data coding: standard libraries—Common Toxicity Criteria 
 Data management: discrepancy, delinquency, communication, correction, and 
preparation of data for analysis 
 
Core benefits of CDMS on NCI-supported multicenter trials: 
 Reduces training costs and overall cost of data management 
 Reduces risk of data delinquency and/or discrepancy 
 Reduces time/effort to correct/complete data 
 Reduces delays in obtaining science and safety results and improves trial 
management and decision making 
 
Other benefits of CDMS on NCI-supported multicenter trials: 
 Supports/complements transformation of groups into a new “network” program  
 Meets Food and Drug Administration (FDA) and other federal requirements for e-
data capture, security, and transfer 
 Promotes data sharing 
 Sets the stage for further infrastructure improvements, such as integration with 
expedited serious adverse event reporting, remote auditing, and electronic filing 
for FDA reports 
 
SOURCE: Doroshow presentation (February 11, 2013). 
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More Collaborations 
One of the IOM recommendations under the broad goal of improving the speed and 
efficiency of clinical trials was to improve collaboration among stakeholders, including within 
NCTN groups and between the NCTN and industry, disease foundations, and patient advocacy 
organizations. 
Renaud Capdeville, vice president of oncology global development at Novartis Pharma 
AG, described several advantages to industry collaboration with the NCTN. In addition to NCTN 
groups and pharmaceutical industry organizations having complementary skills that can be 
leveraged to deliver innovative trials, he said, the extensive network of academic and community 
practices within the NCTN makes it easier to conduct clinical trials on rare diseases. 
“Cooperative groups can reach out to patients quickly,” Capdeville noted. 
Sandra Horning, senior vice president and global head of clinical development of 
hematology/oncology at Genentech, expanded on the advantages of industry-NCTN 
collaboration by noting that collaborative clinical trials offer a lower-cost financial model and 
tap into the operational capabilities of the NCTN. These collaborations provide industry with 
access to patient populations within the NCTN, as well as its disease and scientific expertise, its 
critical mass of U.S. trial specialists, and its innovation in product use and study design. In 
addition, collaborations with NCTN can enhance an industry’s scientific credibility, Horning 
added. But what ultimately drives industry-NCTN collaborations is “a mutual respect and trust, 
and passion for science and improving patient outcomes,” she said. 
Hans-Georg Eichler, senior medical officer at the European Medicines Agency, also 
stressed the advantages of collaborations among stakeholders when it comes to fostering 
innovations in drug regulation (see also the “Regulatory Issues” section). “Collaborations can be 
very effective in stimulating innovation, not only in the technology field but also in the policy 
field, because if one silo says we should go this way, the other silo will immediately say ‘no, 
we’re not going there because it wasn’t invented here.’ Bring those two silos together in the first 
place and you will probably have more success than otherwise,” he said. 
Partnering with Industry 
Several speakers, including Doroshow and Abrams of the NCI and Edward Benz, director 
of the Harvard Cancer Center at the Harvard School of Medicine and president of the Dana-
Farber Cancer Institute, reported that significant progress has been made in facilitating NCTN-
industry collaborations. Doroshow pointed out that the NCI has harmonized all its guidelines for 
programs engaged in the conduct of clinical trials, so that the appropriate incentives are in place 
for collaboration among investigators in different programs. In addition, the NCI, in 
collaboration with the CEO Roundtable on Cancer, developed Standard Terms of Agreement for 
Research Trials (START) clauses for company and academic collaborations to speed clinical 
trial negotiations (NCI and CEO Roundtable on Cancer, 2008).  
The NCI has also revised its intellectual property (IP) option on all Cancer Therapy 
Evaluation Program Cooperative Research and Development Agreements (CRADAs) relating to 
drug development. The IP option clarifies the rights to diagnostics or other IP that might result 
from studying the biomarkers and tissues in the trial. “If a diagnostic is discovered on one of our 
trials, the company who provided the drug and who is our collaborator does not have the first 
right to that diagnostic. The investigator retains that right. On the other hand, there is no blocking 
of the IP so that the company would have to pay royalties every time its drug was used if a 
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regulatory authority said the drug had to be used with that companion diagnostic,” Abrams 
explained.  
Instead, each collaborator receives a nonexclusive, royalty-free, worldwide license for 
research purposes only, and a nonexclusive, royalty-free worldwide license to disclose and 
promote inventions as necessary or as required by a regulatory authority to be used with a drug. 
For alternate uses or dosing schedules for agents being tested in a clinical trial, companies are 
granted a nonexclusive, royalty-free, worldwide license for commercial purposes. But companies 
can still negotiate a co-exclusive or exclusive license for such IP.  
The NCI also established IP terms for investigational multi-agent combination trials, 
which are becoming increasingly common in cancer research. For such studies, each collaborator 
receives a nonexclusive, royalty-free, worldwide license for all purposes, including commercial 
purposes of any combination IP. Companies can still negotiate a co-exclusive or exclusive 
license for a collaborator’s IP pertaining to the agent. To help stem trial start-up delays due to IP 
issues, the NCI set a new absolute deadline of 6 months for CRADA negotiations with industry 
sponsors. 
Benz said that he appreciates the value of this new approach, and noted that  
 
the usual way we’ve set up these intellectual property agreements is based on the bet that 
you’re going to get My Fair Lady instead of the play that never makes it to Broadway. 
Everybody protects jealously that potential big hit, but getting upfront research support in 
return for licensing terms that are friendlier to the pharmaceutical partner is actually a 
better deal. The value of the research support and the chance you have to make an impact 
with present-day support in exchange for a discount down the road in the IP arrangement, 
we think, is a much wiser way to approach it, and it’s been part of allowing us to have 
better relationships with the pharmaceutical industry. 
 
Abrams added that collaboration with industry is more likely “now that we have done a 
number of things to make sure the data quality for the NCTN system is quite high and 
comparable to what’s achieved when industry does a study on their own. Our new IT data 
management system is really state-of-the-art for collecting quality data and is critical to being 
able to go to the FDA and support the needs of our company collaborators.” 
The Web-based IT system also facilitates contracts with research agencies because “it 
doesn’t really matter which group is leading the trial anymore,” Abrams said. He added that “it 
will probably allow us to meet all the new FDA requirements that are upcoming for secure 
electronic data capture and transfer, and will enable our different cooperative groups to 
collaborate on additional scientific projects much more easily and make the data available to 
other people outside the groups more easily.” The IT system also facilitates the systematic and 
all-inclusive reporting of adverse events from Grade 1 to Grade 5, which is necessary for the 
drug registration trials of industry sponsors. 
New aggressive timelines for getting clinical trials under way are also encouraging more 
industry partners to participate, Abrams pointed out. “Our industry colleagues have told us that 
‘time is money.’ We can’t sit around waiting a very long time for NCI studies to get up and 
running.” 
Genentech has had several productive clinical trial collaborations with NCTN, Horning 
noted, and she offered several lessons learned from those collaborations. The NCTN has 
subsequently changed how it conducts such trials to improve future collaborations. For example, 
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one clinical trial collaboration between the NCTN and Genentech, a study of paclitaxel with or 
without bevacizumab in metastatic breast cancer, fell short of FDA data quality standards. This 
led to changes in how NCTN studies with registration potential are conducted, including 
 
 ensuring that safety data have onset and resolution dates;  
 providing more complete safety data rather than just targeted adverse event data; 
 using an internally consistent database with symmetrical data collection on both arms;  
 documenting why physicians or patients stop therapy;  
 having procedures in place to minimize missing forms and fields; and  
 reconciling expedited adverse events with the clinical adverse event database. 
  
The same study raised FDA concerns about investigator bias, which was addressed 
retrospectively through a radiological independent review facility (IRF). Further research by the 
FDA and independent groups indicated that although reader discordance at the patient level was 
common, there was no evidence of systematic investigator bias for the progression-free survival 
(PFS) endpoint (Amit et al., 2011; FDA, 2012a). In addition, these studies found the potential for 
IRF bias through informative censoring. These results led the FDA to propose that when PFS is 
used as an endpoint for clinical trials on agents for solid tumors, a random audit by an IRF could 
avoid some of the missing data issues and mitigate informative censoring, while reducing the 
cost and burden of more complete IRF reviews. 
According to Horning, this example serves to illustrate that industry and NCTN partners 
must clarify regulatory requirements prospectively to satisfy global regulatory authorities when 
they collaborate on clinical trials, because most drugs are registered and marketed globally. 
There also should be prospective agreement between a clinical trials group and an industry 
sponsor of a registration trial regarding data collection and curation; safety reporting and access 
to records; and communications, publications, and presentations; all of which should ensure that 
data are of high quality, reported in a timely fashion, “fit for purpose,” and compliant with 
regulatory requirements, Horning said. (A more extensive discussion of this trial design issue is 
described below in the “Regulatory Issues” section.) 
Ultimately, the data collected must be adequate to reliably assess whether an 
investigational agent has a good risk/benefit ratio when added to or used in place of a known 
standard of care, Horning noted. Safety assessments need to include enough data to assess 
whether there are subsets of patients for whom the risk/benefit ratio is different, she added, and 
critical safety data must be integrated with efficacy data.  
Horning observed that because of lessons learned from previous industry-NCTN 
collaborations, NCTN trials with registration potential have become more “industry-like” in 
terms of data standards, costs, and timelines, characteristics that have increased the likelihood of 
regulatory approval. “The data management improvements address key industry considerations 
for quality, timeliness, and cost,” Horning said. She also appreciated the NCI’s revised IP 
stipulations in the CRADAs, which recognize the value to industry of annotated specimens and 
what they can reveal in the current era, in which predictive diagnostics have become more 
essential to drug development and therapeutic approval.  
In addition, Horning applauded the shortened timeline the NCTN has recently instituted 
between concept submission and trial activation. However, she noted that there is still room for 
improvement in the relatively long time the NCTN takes to prioritize which trials get the final 
green light to go forward—a delay due to numerous discussions among investigators, groups, 
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and NCI steering committees. In contrast, Horning said, this process is much more streamlined in 
Europe, where such decisions are often made at a single meeting, without as much deliberation 
among the various parties involved. 
Global Collaborations 
Horning also stressed the need for the NCTN to collaborate with global partners and 
satisfy global regulatory bodies. This may require ensuring that the patient populations in clinical 
studies represent the diverse ethnic populations that will eventually use the new drug should it be 
approved for the international market. A pre-specified plan for selective data collection must be 
agreed upon not only by the FDA but also by other relevant global health authorities, and more 
effort should be made to harmonize international requirements for global registration trials, 
Horning said. “Trials are now done globally for global registration,” she added.  
Debasish Roychowdhury, senior vice president of global oncology at Sanofi, suggested 
that the NCTN should consider not just European collaborators but also those in other countries, 
such as China.  
Rachel Sherman, program specialist at the Center for Drug Evaluation and Research’s 
(CDER’s) Office of Medical Policy at the FDA, noted that the FDA accepts trials with no 
patients from the United States and has approved drugs based on such studies, but sponsors must 
show that those studies are applicable to the U.S. standard of medical care.  
Richard Pazdur, director of CDER’s Office of Oncology and Hematology Drugs at the 
FDA, also stressed the international scope of drug testing and marketing. “All of the trials that 
come to the FDA at the present time are international trials. For the NCTN to be relevant for the 
next decade or so, they are going to have to address the issue of how they play into not just the 
national cancer trial system, but the international cancer trial system, especially as we take a look 
at rarer and rarer subsets of diseases. The pharmaceutical firms have already realized this and are 
doing trials internationally,” he said.  
Capdeville described the RATIFY2 trial, an innovative, global phase III trial that Novartis 
is conducting in collaboration with CALGB (now part of the Alliance for Clinical Trials in 
Oncology). RATIFY is testing a multitarget kinase inhibitor called midostaurin, which 
preclinical studies showed is especially effective at inhibiting the FLT3 tyrosine kinase. 
Mutations in this kinase are associated with poor survival in acute myeloid leukemia (AML). 
After midostaurin had shown clinical activity in wild-type and FLT3-mutated AML in 
phase I and II trials, Novartis wanted to test it in a phase III trial. According to Capdeville, they 
decided to collaborate with CALGB for this trial because the group had done previous studies 
documenting the prognostic significance for mutated FLT3 in AML and had the scientific 
expertise to run the trial. It was advantageous for CALGB to collaborate with Novartis, he noted, 
because the rareness of the FLT3 mutation in AML would require a large, global multisite study 
to acquire enough patients. “This was beyond what CALGB could deliver in itself, so there was 
this potential synergy with the global operational infrastructure of Novartis that could bring 
together multiple cooperative groups and centers,” Capdeville said.  
RATIFY is a simple randomized phase III study. CALGB was responsible for writing the 
protocol for the trial, with input from the other 12 participating cooperative groups (in the United 
States and internationally). CALGB owns the database and is responsible for reviews by a Data 
and Safety Monitoring Board on a regular basis. CALGB has sponsored the trial in North 
America and Novartis has sponsored the trial outside North America. CALGB and the other 
                                            
2 Randomized AML Trial In FLT3 in <60 Year Olds. 
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cooperative groups share accountability for FLT3 testing. If the study is successful, Novartis will 
submit its findings for regulatory review. A joint clinical trial team oversees day-to-day 
operations. 
The main challenge in the trial has been to detect the FLT3 mutation in tumor samples 
before patients receive chemotherapy, given the clinical urgency of the diagnosis, Capdeville 
noted. That testing is completed within 3 days of sampling at one of the 10 central labs in each of 
the main cooperative groups. There is a common protocol for consistency and periodic cross-
validation of the test sample among laboratories.  
After meetings with the FDA, trial leaders decided that a companion diagnostic would be 
developed at a later stage in drug development, with a bridging study aimed at showing 
concordance between the clinical trial assay and the companion diagnostic version of the assay. 
This required patients to consent to their samples being used not only for the phase III clinical 
trial, but also for the later bridging study, as well as central storage of all tumor samples. 
The study is ongoing, but Capdeville listed several lessons that have already been learned 
from the collaboration: 
 
 Keep the data flow as simple as possible 
 Foster open and transparent collaboration between industry and the cooperative 
groups, “which takes some time so the two understand each other well and 
expectations are well aligned,” Capdeville said. 
 Be open to using a slightly different process than normal. “We can’t just use the 
Novartis SOP [standard operating procedure] or only the cooperative group SOP, so 
there has to be dialogue on this,” Capdeville pointed out. 
 Preserve the independence of scientific and academic oversight on the study while 
balancing industry’s needs. 
 Involve a range of disciplines, including technical as well as scientific expertise. 
Partnering with Cancer Centers 
Benz reported that the Dana-Farber Cancer Institute recently reorganized its oncology 
research program to better enable clinical translation. Prior to the reorganization, which began in 
2002, most of the cancer research resources were devoted to disease programs and centers that 
were anatomically focused. These centers were the sites of Dana-Farber’s clinical trial activity, 
except for phase I studies, which stemmed from the institute’s Early Drug Development Center. 
Although the centers were multidisciplinary, including surgery, radiation, oncology, nursing, 
pharmacology, and medical oncology, “they were becoming somewhat siloed around their 
particular cancers that they were interested in,” said Benz. 
Recognizing that this setup was slowing the pace of clinical translation, Dana-Farber 
made a number of changes. One change was to recognize that the ultimate end product “wasn’t 
papers published in Nature or other academic metrics, but the goal would be to bring things into 
clinical practice,” Benz said. The restructuring aimed to implement project management 
principles that would translate discoveries into clinical benefit while preserving the culture of 
independent discovery. Dana-Farber faculty identified 12 areas ripe for translation, such as 
genomics, vaccines, and systems biology, and created “integrative research centers” around each, 
Benz reported.  
Although some of these integrative research centers, such as the Center for Cancer 
Genome Discovery and the Center for Functional Cancer Epigenetics, focus on research pursuits 
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grouped according to the primary method or technology being employed for discovery, Benz 
stressed that they are not traditional core facilities. Instead, they provide both a technology 
platform and an intellectual hub, and membership in each crosses departmental boundaries.  
The centers are girded by business rules and accountability. The faculty leader of each 
center is charged with developing a business plan that explicitly includes milestones and 
deliverables over 5 years. The financial plan requires the center to be self-sufficient within the 
same time frame. “Whether it is mouse modeling, lead molecule development, or other projects, 
the expectation is that the work will move something closer to a clinical application,” Benz said.  
To incentivize faculty to lead the centers, Dana-Farber created opportunities for 
responsibility and career advancement, and provided seed funding to start center activities. “We 
created a place in the institution where scientists with this kind of background and orientation 
had a home and could make a contribution with professional upward mobility,” Benz stressed. 
“We realized that we had capabilities that were scattered across various labs and needed to be 
organized into programs,” he said. For example, a Cancer Chemical Biology program was started 
with three recruited faculty who had synthesized materials in their own laboratories. These newly 
discovered agents were about to enter or were already in clinical trials.  
One of the centers, the Belfer Institute for Cancer Sciences, aims to bridge the gap 
between academia and industry. Researchers at the Belfer Institute have expertise in preclinical 
models, including genetically engineered mice, primary tumor xenografts, and short-term tissue 
cultures. They are also well versed in biomarkers and clinical biomarker assays and have access 
to clinical specimens through academic collaborations with a broad network of investigators. The 
Belfer Institute has been partnering with large pharmaceutical firms such as Merck and Sanofi to 
identify and validate new drug targets and delineate a clinical path for drugs in clinical trials. 
“The Belfer creates an interface where faculty or any kind of external partner can bring a target 
molecule and get the studies done that they need to do to decide if it should end up in an early-
phase clinical trial,” Benz said. 
Dana-Farber has a more traditional and longstanding partnership with Novartis that 
enables Dana-Farber researchers to receive 2-year research grants from Novartis on topics of 
interest to the company. The researchers have the freedom to publish their findings. “A lot of 
oncology drugs in Novartis’s pipeline have moved through that pipeline a little faster thanks to 
these partnerships,” Benz said. 
Benz summarized what Dana-Farber has learned from its restructuring and industry 
partnerships in terms of what it takes to move things more quickly from bench to bedside. “You 
need a great group of investigators, and they have to be a mix of basic, clinical, and translational 
scientists who want to collaborate and interact in this more team- or goal-oriented scientific 
application,” Benz said. He stressed that these investigators have to be situated in a place where 
there is expertise and understanding of what the clinical problems are. “They can’t be purely 
clinical centers, but must also have many of the features of a strong academic partner,” he said. 
Another necessary ingredient is technical expertise, and “a broad interface that allows multiple 
points of entry, exits, and reentry for this process of partnering and translation outside of the 
immediate sphere,” Benz noted.  
Partnering with Foundations 
There are also many potential benefits for the NCTN in partnering with disease-specific 
foundations, as well as with more general foundations, Benz pointed out. Margaret Anderson, 
executive director of FasterCures, agreed, noting that venture medical philanthropy is a growing 
area. Venture philanthropy not only funds novel, high-risk research that bridges disciplines, 
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institutions, and ideas, but also taps strong scientific expertise to guide its efforts, she said. 
“Venture medical philanthropy groups tear down some of the collaboration barriers due to the 
silos that exist in medical research,” Anderson added. Disease foundations also tend to have a 
great deal of oversight in whether the funds they provide are being well spent. “The hallmark of 
all these groups is if they are going to put a dollar down on the table for any activity, they’re 
going to monitor that money and look at how it is being spent and what the outcome is,” she 
said. 
Some medical philanthropy organizations run entire trials themselves at various 
institutions, or support clinical centers that do so. For example, she said, the Multiple Myeloma 
Research Consortium has 16 member institutions and has initiated 30 trials, which launched 60 
percent more quickly and enrolled patients 10 percent more quickly than industry trials. Eight of 
these drug studies are in their final stages. Venture medical philanthropies can also bankroll 
industry endeavors that prompt pharmaceutical firms to develop treatments for a specific disease 
they are not already inclined to explore on their own, Anderson added. She highlighted the recent 
approval of Kalydeco, the first drug to target the cause of cystic fibrosis—the protein product of 
a faulty gene (CFF, 2012; FDA, 2012b). This drug resulted from a longstanding collaboration 
between the Cystic Fibrosis Foundation and industry, in which the foundation provided much of 
the seed capital needed to launch the clinical development of the drug.  
Anderson stressed that one should consider not only financial capital but also human 
capital when evaluating whether collaborations furthered by venture medical philanthropy will 
be productive and valuable. If patients trust advocacy organizations and foundations, they will be 
more willing to participate in the research they sponsor; these organizations “are really changing 
the game of clinical trial recruitment,” Anderson said. She noted that the Michael J. Fox 
Foundation for Parkinson’s Disease has its own “trial finder,” which had 14,000 patient 
volunteers and 200 clinical trials in its database within 10 months of being launched in April 
2012. “It’s absolutely critical that you have clinical trial matching like this because oftentimes 
patients are not going to be finding out about these trials from physicians,” Anderson said. She 
added that the clinical center associated with the Translational Genomics Institute has 60 percent 
of patients participating in clinical trials, compared with the national average of 3 percent. 
“Venture medical philanthropy is fixing the leaks in the clinical trial pipeline that are 
diverting the stream of patients from such trials,” Anderson concluded. Improving the efficiency 
of trials will encourage broader participation by both physicians and patients. 
In addition, many disease foundations have longstanding relationships with FDA staff, 
which “really paves the way for things to go more quickly. They do regulatory de-risking,” 
Anderson said. “They lay the groundwork for determining and answering the questions the FDA 
needs answered to start looking at approvals in this space.” 
Anderson ended her presentation by stressing that “now’s the time to start to look at 
efficiencies and ways to potentially leapfrog things forward and think about how we can change 
this, because the bottom line is that if we’re not patients already, we’re going to be.” 
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An Example of Collaboration in Cardiovascular Research  
David Sabatine, associate professor of medicine at Harvard Medical School and associate 
physician of cardiovascular medicine at Brigham and Women's Hospital, described the TIMI 
Study Group, which he chairs. The TIMI Study Group,3 which was named for its first trials on 
thrombolysis in myocardial infarction, is an academic research organization based at Harvard’s 
Brigham and Women’s Hospital dedicated to advancing the knowledge and care of patients with 
cardiovascular disease and its risk factors. Since 1984, TIMI has conducted 65 clinical trials at 
more than 4,000 sites across 6 continents. More than 8,000 investigators have participated in 
TIMI trials, which have enrolled more than 300,000 patients to date. Most TIMI trials are 
sponsored by industry and enroll between 15,000 and 25,000 patients per trial. 
Sabatine explained how the TIMI Study Group operates and how it collaborates with 
industry in conducting clinical trials. He noted that pharmaceutical companies choose to work 
with TIMI because it offers experienced and skilled research scientists, clinical trialists, and 
project managers. “These trials are so big, they are like a jumbo jet—they’re very hard to steer so 
you need a lot of expertise to fly them,” Sabatine said.  
Another advantage of TIMI’s infrastructure, Sabatine noted, is that “it brings all the 
necessary parts together under one roof. The principal investigator works very closely with the 
project director, who works on a daily basis to ensure all aspects of the trial are integrated. So, if 
we wanted to have a high rate of adjudication of events, for example, someone can take care of 
that by walking down the hall and talking to one of his or her colleagues.” The TIMI Study 
Group also offers core services that include a safety desk; trial hotline; biomarker, genetics, and 
electrocardiography core laboratories; a clinical events committee; and a quality-assessment 
team. 
Monitoring of the trials is typically done by contract research organizations hired by 
industry sponsors, but the monitors are trained by the TIMI Study Group on the disease state and 
the study protocol. “We sort of take charge of them, but they aren’t on our payroll,” Sabatine 
said.  
TIMI physicians include 
 
 clinicians on the staff at Brigham and Women’s Hospital; 
 global principal investigators for trials who come from the faculty at Harvard Medical 
School and dedicate between 75 and 80 percent of their time to research; and  
 clinical trialists (TIMI investigators), who are highly experienced in the design of 
clinical trials and work daily with the senior project director on trial implementation. 
  
The TIMI Study Group also focuses on ensuring adequate training and communication 
for participating sites, according to Sabatine, and has a trial hotline, staffed 24/7, that responds 
to all medical and operational inquiries.  
TIMI project managers generally have more than 10 years of experience in running 
mega-trials with more than 10,000 patients. “There’s a special skillset for running such large 
trials and our project managers have the experience that is required and that even industry may 
lack,” Sabatine noted. TIMI staff also apply their expertise to develop an appropriate trial design 
that includes the right patient population, drug dose, and endpoints. This effort is aided by the 
TIMI Working Group’s online databases of electronic patient records collected during its trials. 
                                            
3 See http://www.timi.org. 
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Researchers can tap that database to refine inclusion and exclusion criteria for their trials. “We 
work very closely with the sponsor beforehand, using our databases to give information on what 
might be the right enrichment factors for the trial,” Sabatine said.  
As Figure 2 illustrates, each TIMI trial has a joint management team with members from 
both industry and TIMI, including key physicians, study chairs, and sponsor representatives, who 
meet biweekly.  
 
EXEC CMTE 
5-7 members; meet 6x/yr 
Study Chairman, PI, 
Other MDs, Sponsor 
STEERING CMTE 
~40 members; meet 3x/yr 
EC + NLIs 
CLINICAL SITES 
JOINT MANAGEMENT TEAM 
Biweekly Mtgs 
Study Chair, PI, Co-PI’s, Dir Ops, Sr PD 
Sponsor Med & Ops Leads 
JOINT WORKING GROUP 
Weekly Mtgs 
Operational & Med Personnel 
CEC 
Safety Desk 
Study Drug 
IXRS 
Core Safety 
Labs 
Database 
Independent 
Biostatistics 
Monitoring 
IDMC 
SPONSOR TIMI 
Biomarker and
Genetic Cores 
Statistics 
TIMI 
 
 
FIGURE 2 TIMI trial organization. 
NOTES: CEC = Clinical Events Committee; Dir Ops = Director of Operations; EC = executive 
committee; EXEC CMTE = executive committee; IDMC = Independent Data Monitoring Committee; 
IXRS = interactive voice recognition/website system; MDs = medical doctors; Med = medical; Ops = 
operations; Mtgs = meetings; NLI = national lead investigator; PI = principal investigator; Sr PD = senior 
project director; STEERING CMTE = steering committee; TIMI = Thrombolysis In Myocardial 
Infarction; x/yr = times per year. 
SOURCE: Sabatine presentation (February 11, 2013). Reprinted with permission from TIMI. Not for 
reproduction without permission from TIMI. 
 
In addition, a joint working group focused on operational issues meets weekly. Often, 
there is also joint management of the blood samples collected in the trial. The samples are 
typically split between TIMI and the sponsor, according to Sabatine.  
Open and frequent communications between sponsors and TIMI gird the success of its 
collaborations with industry, he noted. “We have very frank conversations at the beginning of 
any potential marriage with our sponsors that set the boundaries and reinforce respect for and 
trust in the area of expertise each group will have,” Sabatine stressed. He added that during a 
trial, there are ongoing discussions with industry sponsors about all aspects of the study, 
including protocol design and the statistical analysis plan. “We maintain a dialogue with our 
sponsors throughout the half a decade that we work together,” Sabatine said.  
Regarding legal agreements for the TIMI-industry collaborative trials, Sabatine noted that 
because of the long track record TIMI has with a number of companies, “we don’t need to 
reinvent the wheel but just specify the scope of work for a particular project.” He added that 
Harvard has strict rules that give TIMI some ownership of the data and the ability to publish 
results. 
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TIMI relies on industry support. Most TIMI trials are funded by industry, Sabatine said, 
“and it’s my job to keep the trials coming” to ensure financial support of TIMI’s infrastructure.  
In response to a question about what motivates clinicians to participate in TIMI trials, 
Sabatine noted that participating study sites are not dedicated solely to TIMI trials: “There’s no 
pledge of allegiance to TIMI, but they do tend to work with us frequently because we spend a lot 
of time designing trials that are high-quality and high-profile.” The findings of many of the 
studies are published in prestigious scientific journals. Meaningful physician-to-physician 
contact also motivates doctors to participate in the research, Sabatine added. “If there’s a 
question from the site, they can talk to the TIMI investigator who’s spending 75 to 80 percent of 
his or her time on the trial,” he said.  
Participating physicians are rewarded by the scientific success of the trial, according to 
Sabatine, and are also given financial compensation for their time. Sponsors determine how 
much participating physicians are paid per patient enrolled in the trial. “We advocate for the 
highest, most reasonable amount, but the sponsor ultimately determines the dollar value and that 
ends up being constant for all the sites,” Sabatine said. 
The Timeline for Cancer Drug Development 
To provide a perspective on the challenges involved in conducting efficient cancer 
clinical trials, Joseph DiMasi, director of economic analysis at the Center for the Study of Drug 
Development at Tufts University, presented data on clinical development and approval times for 
cancer drugs. He showed that antineoplastic drugs have long development timelines compared 
with most other therapeutic classes, and that development times are increasing. Clinical 
development times for cancer drugs between 2006 and 2011 were 8.2 years on average, vs. 7.6 
between 2000 and 2005 (see Figure 3). In addition, only 13 percent of anticancer compounds that 
enter the clinical testing pipeline actually get approved. More detailed analysis revealed that 
drugs for blood cancers are nearly four times more likely to be approved than those for solid 
tumors, and that the risk of drug development failure varies significantly by cancer type, but not 
by molecule size.  
DiMasi also showed that despite long development times, the number of anticancer drugs 
approved in 2012 was more than twice the average annual rate for the previous decade. In 
contrast, drug approvals for all other therapeutic classes decreased or remained essentially flat 
during the same time frame (Kaitin and DiMasi, 2011). The number of cancer drugs entering the 
clinical pipeline between 1993 and 2004 has also markedly increased, DiMasi said. “This is 
further evidence of increasing interest in cancer drug development, despite all the problems with 
this development alluded to thus far,” he concluded. 
The time from first submission of a new drug or biologic application to FDA approval 
also varies by drug category, with shorter times for antineoplastic drugs than for most other 
therapeutic drug classes (in contrast to the overall clinical development time). About 80 percent 
of that time comprises FDA review of the application, and the remaining 20 percent comprises 
sponsor responses to FDA requests. Between 2006 and 2011, approval times for cancer drugs 
decreased by half compared to what they been between 2000 and 2005 (0.6 vs. 1.2 years). 
Although more oncology drugs are on fast-track, accelerated approval programs than compounds 
in other therapeutic classes, that special designation was not linked to shorter approval times by 
either the FDA or the European Medicines Agency (EMA), DiMasi noted. “Oncology drug 
development is challenging, and we need efficiency improvements to lower cost, speed 
development and regulatory review, and to reduce risk in this critical therapeutic class,” he 
concluded. 
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FIGURE 3 Clinical development times vary by period and across therapeutic classes, 2000-2011. 
SOURCE: DiMasi presentation (February 11, 2013). 
NOTES: CNS = central nervous system; *excludes AIDS Antivirals. 
 
 
FOSTERING INNOVATION 
As a preface to discussing the IOM recommendation to incorporate innovative science 
and trial design in cancer clinical trials, one session of the workshop was devoted to exploring 
the latest advances in “precision” medicine (also referred to as “personalized” medicine) and the 
challenges in implementing these new technologies in clinical care. Levi Garraway, principal 
investigator and associate physician at Brigham and Women’s Hospital and assistant professor of 
medicine in the department of medical oncology at the Dana-Farber Cancer Institute, began this 
session by pointing out that for several major tumor types, including melanoma and breast, 
colorectal, lung, ovarian, and brain cancers, about half of those tumors harbor at least one 
identifiable genetic alteration that fosters tumor growth or survival and is “actionable.” He said 
that an actionable alteration is one that can be targeted by approved or experimental drugs, or 
one that suggests the inappropriateness of treatment using particular agents. “That alteration is 
not just for the cancer biologist to get excited about, but is actually something that may evoke, in 
the back of a clinician’s mind, a decision or a different choice of care,” Garraway stressed.  
Many agents that target genetic pathways in cancer have already entered clinical trials. 
Garraway said, “We have all the ingredients needed to practice precision medicine. There is not 
just one, but multiple drugs in development targeting multiple components in these genetic 
pathways. We now have the technology to look for those genetic alterations that will enable us to 
match the right tumor to the right drug.” 
But such matching is currently easier said than done, several speakers pointed out. “It’s 
like the genomic super highway is meeting the bike path of clinical medicine,” Garraway said, 
due to both scientific and logistical challenges. These challenges include acquiring tumor 
samples, the genetic heterogeneity of those samples, developing innovative clinical trial 
strategies that can apply the genetic findings, and addressing issues related to quality control and 
reimbursement for biopsies and tests.  
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Collecting Biospecimens 
Among the logistical challenges is the need to obtain consent from patients to submit to 
biopsies and extensive genetic testing of their tumors and to appropriately counsel them about 
what the results mean. Walter Curran, executive director of the Winship Cancer Institute of 
Emory University and professor and chair of radiation oncology at Emory University School of 
Medicine, noted that the NCTN has trials that require patients to submit a tumor tissue sample in 
order to enroll. “But it’s still a work in progress for those trials where it’s not required for 
registration, and the more our tumor banks provide community physicians with kits that allow 
their staff to [submit a tumor tissue sample] more readily, the better,” he said.  
Peter Adamson, chair of the Children’s Oncology Group (COG) and chief of the Division 
of Clinical Pharmacology and Therapeutics at the Children’s Hospital of Philadelphia, said that 
his cancer center obtains tissue for the majority of its studies and analyzes that tissue to 
determine which trial a patient might be eligible for. COG also aims to have a tissue sample 
submitted at the time of diagnosis for every child they treat with cancer. Charles Blanke, chair-
elect of SWOG and professor of medicine at the Oregon Health and Science University Knight 
Cancer Institute, added, “This is a real culture change. Ten years ago, if you had mandated a 
biopsy, the IRB would have said, ‘Absolutely not.’ Now these patients are not only asking for 
biopsies when they go on trial, they also want to be biopsied when they progress. At SWOG 
we’ve been able to collect specimens on 86 percent of patients in our trials that just requested, 
rather than required, the samples.” Robert Comis noted that about 90 percent of patients 
enrolling in ECOG-ACRIN trials consent to having their tissue sampled and stored. “We all have 
huge banks of tissue and tremendous opportunities to use our annotated specimens, and those 
findings can be correlated with images that are integrated into the same system,” he said.  
But it can still be problematic to discern which genetic findings from tumor tissue should 
be conveyed to patients. David Solit, associate professor at the Human Oncology and 
Pathogenesis Program in the Department of Medicine at Memorial Sloan-Kettering Cancer 
Center, noted that “eventually, we’re going to find inherited genetic alterations that predispose 
patients to cancer, and the question is how much of that information has to be returned to the 
patients, and do we need medical geneticists and counselors to be involved in this process if we 
find this inherited risk?” In addition, sometimes the testing reveals genetic flaws not currently 
targeted by drugs on the market or by experimental agents being tested in clinical trials to which 
the patient has access. Other times, appropriate trials may be available, but patients and their 
physicians may not be aware of them, Solit said. 
Another potential challenge is to have adequate biopsy tissue available for genetic 
profiling, not only at the time of diagnosis, but also when a tumor progresses, in order to assess 
the cause of treatment resistance and how to target that resistance. “There’s a lack of tissue for 
some patients. About 15 percent of patients don’t have any clearly accessible tissue you can use 
for profiling,” said Solit. Others may not have enough tissue for the multitude of tests that may 
need to be done by multiple labs, added Vincent Miller, senior vice president of clinical 
development at Foundation Medicine, Inc. Researchers continue to identify relevant new genetic 
alterations, and the tests for those changes continue to be developed. “The worst situation we 
may be placed in as the clinician is, we only have two slides left to do four different tests. 
Choosing which tests to do in that circumstance is like Russian roulette,” Miller said.  
Solit also noted that the genetic heterogeneity of tumor cells can pose sampling 
conundrums, and that metastatic lesions may harbor different mutations than the primary tumor. 
For example, he described a study of paired primary and metastatic tumors from melanoma 
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patients in which mutations in the BRAF4 gene were relatively common in both the primary and 
metastatic samples, while mutations in the PTEN5 gene were rare in the primary tumors and 
common in the metastatic tumors. 
There also should be adequate reimbursement for the effort involved in biopsying or 
rebiopsying tumors for the purpose of genetic profiling, one workshop participant stated. 
Hospitals are not always willing to pay for that expense, nor are providers or insurers. The 
participant suggested that the NCI provide the financial resources for such biopsies. Marshaling 
adequate resources for the profiling itself is another major financial challenge.  
Testing Biospecimens 
Several speakers stressed the lack of quality control for genetic profiling. “We need 
credentialed assays,” Solit stressed. Miller added, “We need to develop common criteria for the 
testing we accept for our clinical trials.” Lisa McShane, mathematical statistician at the 
Biometric Research Branch in the Division of Cancer Treatment and Diagnosis at the NCI, noted 
that often there is variability in results from laboratories doing the same test, which could be an 
argument for central testing, although this could raise logistical problems. She pointed out that 
more than a dozen years after the first test for HER2 (human epidermal growth factor receptor 2) 
was used to predict the response of breast cancer patients to the drug Herceptin, there is still a 
debate about the best way to measure HER2. McShane added that how specimens are handled 
and processed can also affect the results of the tests. “How can we make sure that when your 
sample is taken, it is treated appropriately?” she asked.  
Interpreting Molecular Tests 
A major scientific challenge to precision medicine for cancer is interpreting the large 
datasets that result from genomic sequencing and distinguishing driver mutations from passenger 
mutations. “The number of data points per patient is skyrocketing, and we need clinical data 
interpretation algorithms that are capable of addressing this,” said Garraway. Often, there are 
genetic variations of unknown significance for a particular tumor, but for which there is a 
targeted drug. In these instances, in vitro models or clinical tests could help assess if the genetic 
change is significant for that patient. 
Genomic sequencing reveals a large of number of genetic alterations in tumors, some of 
which are what Garraway called “mountains,” or common alterations, but many more of which 
are “hills,” or mutations that occur less frequently. “The hills outnumber the mountains, and 
they’re critically important” in determining the treatment of individual patients, Miller said. “The 
number of clinically relevant alterations in a single patient is low, but the number of clinically 
relevant alterations across the disease state is high,” he explained. “Some genes are altered only 
in 1 to 5 percent of [a certain histological type of] tumor and often in a non-predictable fashion, 
arguing for broad-based tests and nimble trials that can accommodate patients with these rare 
mutations.”  
Solit noted that one patient whose tumor was assessed using whole genome sequencing 
had 19,000 mutations because of a defect in a DNA repair pathway. Because she responded to 
the combination of drugs given to her in a phase I study, Solit was able to determine that this 
defect was a driver mutation, even though it was not part of the standard 300-gene assay 
                                            
4 Human homolog B of v-raf (Rapidly Accelerated Fibrosarcoma viral oncogene). 
5 Phosphatase and tensin homolog, a tumor suppressor gene. 
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normally used to detect relevant mutations. But often, he said, the drivers are difficult to 
ascertain.  
Garraway added, “One reason we discover the same driver mutations over and over again 
is because we recognize them, but there are always recurrently mutated genes that we don’t 
recognize.” He noted that once more tumor genomes are sequenced, clinically annotated, and 
compiled in a central database, more rare mutations will be identified as being driver mutations. 
“It is still humbling how little we know,” Garraway said. 
Solit stressed that “the way you figure out if these genetic changes are drivers will not be 
in the lab. You need a clinical link that will tell you that particular mutation was important. This 
is opposed to what we’ve been doing, which is to sequence 150 or 200 genomes and then find 
the most common mutations and validate them in the laboratory.” 
In his presentation, Solit showed that the rare clinical remissions that patients experience 
after being treated with investigative agents can signal driver mutations that, although rare in 
patients with a particular type of cancer, may also occur in several other types of cancers and 
therefore offer cross-disease treatment opportunities. When Solit has encountered these 
“exceptional responders,” genomic sequencing of the patients’ tumors has revealed rare 
mutations in genes that are part of the genetic pathways targeted by the drugs with which they 
were treated (Kaiser, 2013). These rare mutations explain why a few patients responded so 
favorably to a treatment when most of the patients in their study cohort, all of whom had the 
same histological type of tumor, did not. “It was not so surprising that these patients 
responded—the surprise was that they had this mutation we didn’t know about before,” Solit 
said. 
Given the value of such discoveries, several speakers suggested that there is a need to 
develop and validate profiling technologies so that all cancer patients can have their tumors 
genetically profiled and receive cancer treatments matched to their profile. “Each patient’s 
treatment needs to be informed by an understanding of the molecular changes driving his or her 
disease—and what you don’t look for, you won’t find,” Miller said. 
In his presentation, Miller described the approach developed by Foundation Medicine, a 
cancer diagnostics company that provides clinical laboratory services intended to help physicians 
tailor cancer therapy based on genomic analysis of each patient’s tumor.6 Using “next-generation 
sequencing” (NGS), Foundation Medicine sequences the coding region of more than 200 cancer-
related genes, as well as 48 introns in 20 genes frequently rearranged in human cancer. “The 
premise of our test is to [look at the approximately 1 percent of genes] that are unambiguously 
implicated to be somatically altered in human cancer and study the heck out of them both in 
breadth, by looking broadly across tumor types, and in depth, by obtaining tremendous 
coverage,” Miller said.  
According to Miller, Foundation Medicine’s assay is optimized for use with fine needle 
aspirations, core biopsies, and malignant effusions, and often identifies alterations that would 
never have been tested for because they are not the common mutations found in a given patient’s 
particular histological type of cancers. He said that Foundation Medicine translated research 
grade NGS into its clinical cancer diagnostic assay by doing extensive analytic validation, which 
he said demonstrated the high accuracy and reproducibility required for clinical use. Miller said 
the assay can identify base substitutions with a sensitivity of greater than 99 percent for minor 
allele frequency greater than or equal to 5 percent, small insertions or deletions with a sensitivity 
of greater than 98 percent for minor allele frequency greater than or equal to 10 percent, and 
                                            
6 See http://www.foundationmedicine.com. 
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copy number alterations (amplification or homozygous deletion) with a sensitivity greater than 
95 percent. He added that the specificity of the assay is greater than 99 percent (Yelensky et al., 
2013). 
After tumor samples have been tested, Miller explained, experts at Foundation Medicine 
integrate the genomic information into a report in a format understandable for both physicians 
and patients. “Our approach has been to link genome technology, clinical oncology, cancer 
biology, and information science to make this test applicable to routine clinical practice,” Miller 
said. Sometimes Foundation Medicine’s assay reveals aberrations that could potentially be 
targeted by drugs that are in clinical trials, but the trials may not be available locally, and patients 
are not always entered into trials, Miller noted.  
Foundation Medicine also collaborates with several pharmaceutical companies to identify 
biomarkers in clinical trials. Some of these trials are “rescue” trials for drugs that failed previous 
clinical trials because of a lack of enrichment of the study population with patients most likely to 
respond to the drug. Others are longitudinal studies aimed at uncovering causes of treatment 
resistance that develop over time. Foundation Medicine also works with pharmaceutical firms to 
conduct prospective studies in which individuals are assigned to a line of therapy based on the 
presence or absence of one or more alterations in a gene or a series of genes, Miller said. 
Innovative Trial Designs 
Solit’s findings from exceptional responders in clinical trials also suggest the need for an 
innovative clinical trial design that tests the same agent on people with a wide range of cancer 
types, he stressed. He proposed conducting what he called a “basket” study, in which a treatment 
for a specific genetic defect in a tumor is tested on multiple cancer types, each of which is put 
into its own basket, or arm, of the study. For example, a BRAF inhibitor may be tested on a 
small group of colorectal patients while simultaneously being tested on a small group of lung 
cancer patients or ovarian cancer patients, all of whom have a BRAF mutation and are under the 
same phase II clinical trial umbrella. “There are more than 400 different histological subtypes of 
cancer, but you can’t open up 400 BRAF inhibitor studies. However, you can open up one basket 
study that potentially will bring all these patients in to answer a particular hypothesis,” said Solit. 
Solit noted that some researchers are proposing to set up “an umbrella of basket studies, 
which would allow one of these studies in a modular way to be brought out to participants in a 
network such as the NCTN or some other large network without requiring you to go through 
each individual IRB for each disease.” The advantage of such a setup would be the data collected 
from the studies, which would be valuable to patients, doctors, payers, and regulatory authorities, 
he added. “We want to be able to capture this data because if patients are just being treated ad 
hoc in the community based upon a commercial laboratory giving them a result and no data is 
then being disseminated, other patients with the same mutation are not going to benefit by the 
information gained from treating previous patients. We need a new design to do this and a group 
that’s willing to lead that effort,” Solit stressed. Miller agreed, adding, “Use of a broad, robust 
testing platform in concert with an effective ‘master’ clinical trials network should accelerate 
accrual to trials, minimize off-label use, and allow patients access to agents more likely to be 
effective for them.” 
Sometimes, a basket study may discover tissue differences that affect response to a drug 
targeting a specific mutation—a BRAF inhibitor may not work as well in a colon cancer tumor 
with a BRAF mutation as it does in a melanoma with the same mutation, for example. But if a 
basket trial shows this variation, it is still valuable, clinically relevant information, Solit noted. In 
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addition, any arm/basket in a trial could be amended during the study to test a different treatment 
if the first 15 patients with a particular type of cancer do not respond, for example.  
In response to a question regarding how many patients have to be screened to discover 
the rare mutations needed for a basket trial, Solit replied, “It is my hope that we’re not going to 
screen any patients, but rather rely on the entire country screening patients and identifying those 
with the mutations targeted in the basket trial. The screening protocol should be separated from 
the treatment protocol. If we have a study of 200 patients where we’re screening them using a 
similar assay for every patient, we’re not going to be able to find enough patients for the clinical 
trial we want to do.”  
For patients whose tumors have multiple drivers, it will be difficult to decide how to fit 
them into basket studies that offer a treatment targeting only one of the drivers. George Sledge, 
chief of oncology in the department of medicine at Stanford University, pointed out that one 
study of 100 breast cancers found 40 drivers in 73 different combinations, and most of those 
drivers occurred with low frequency (Stephens et al., 2012). Solit acknowledged that this is a 
problem that current basket studies are not designed to address, but he added, “First we need to 
get data on the single agent and then if we find that all the patients with a specific doublet 
mutation don’t respond, we need to start looking into that combination. The only way to study 
that is to start sorting through it clinically, and we could capture some low-hanging fruit and help 
a lot of patients in the short term just by doing these basket studies.” Miller agreed, adding, 
“There’s not a trial for everybody, but from looking at the data, 80 percent of patients could fit 
into a study of treatments that target doublet or triplet genetic drivers.” 
McShane noted that basket trials can be logistically efficient and innovative “because we 
have a big screening protocol that brings everybody into the same front door and then directs you 
to separate, individual, single-arm trials.” But she cautioned that it will be critical to consider 
what the right endpoints are for basket trials. A response endpoint might not be appropriate for a 
targeted therapy that results in stable disease rather than dramatic tumor regression. But using 
PFS as an endpoint can be problematic if the genetic aberration or other biomarker used to select 
treatment is also associated with a more indolent course of disease or slower progression. 
McShane suggested that randomization of patients within the same biomarker subgroup could 
address this potential source of bias because it would distinguish prognostic from predictive 
effects. For example, patients could be randomized to receive standard therapy with or without 
the new targeted agent. 
McShane stressed that “innovation is great, but we have to make sure the innovative 
methods still answer the questions that need to be answered.” She gave examples of other 
innovative biomarker-based clinical trial designs (Freidlin et al., 2010), including a biomarker 
enrichment design used to identify breast cancer patients likely to respond to Herceptin. In this 
design, patients whose tumors were positive for HER2 were randomized to be treated with 
Herceptin or to standard therapy. The control arm was necessary because HER2 is a negative 
prognostic marker for breast cancer. But this trial design meant the results could not predict how 
patients without the HER2 marker would do when treated with Herceptin. “We’re still debating 
this because the enrichment design doesn’t really let you know what’s going on with the marker-
negative patients,” McShane said. 
To “hedge their bets” in this type of situation, researchers can conduct a biomarker-
stratified design in which all patients are tested and then randomization is stratified by test 
results, McShane said. Patients who test positive or negative for the biomarker are both 
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randomized to receive the new therapy or standard therapy. However, it is difficult to accrue 
patients to such a trial because the test results are not used to select therapy. 
McShane also noted that there are multi-arm trial designs for non-biomarker-guided 
therapies. These can be statistically efficient by enabling reuse of a control arm, thereby reducing 
the number of patients needed to answer scientific questions. Adaptive designs are another 
innovative type of trial that use interim monitoring to determine when to stop the trial, when to 
increase the number of patients put on treatment arms that appear to be more effective, or when 
to drop ineffective treatment arms. “These can all be handled statistically—it just has to be pre-
specified in the analysis plan,” McShane said. 
McShane also pointed out that joint phase II/III trials are increasingly being employed to 
avoid bottlenecks in trial development and patient accrual. In these trials, phase II patients are 
seamlessly followed in phase III, assuming that the phase II results were reasonably promising. 
But it’s important to choose the right endpoint for progressing into the phase III portion in such 
trials. A popular endpoint in this type of study is pathological complete response, but a recent 
study of breast cancer did not find a strong association between a pathological complete response 
and overall survival (Cortazar et al., 2012). “This is just a word of caution that we can be 
innovative and make assumptions, but we have to be doing some reality checks to make sure that 
what we’re going after is the right thing,” said McShane.  
Garraway described an innovative model for clinical translation of precision medicine, 
known as Can Seq. The Dana-Farber Cancer Institute, working with the Broad Institute, recently 
launched this prospective trial, which conducts whole exome sequencing on the tumors of every 
patient in the trial. Researchers use the exome sequences to provide a list of variants with 
potential clinical implications, i.e., those that are prognostic, indicate what drugs might be 
effective, or suggest dose. This list is reviewed by a committee comprised of experts in oncology 
and genetics, who then compose and send a report with the most clinically relevant information 
to the treating oncologist. The trial is enrolling patients with metastatic lung, colorectal, prostate, 
and breast cancers. Garraway described one example from the trial in which exome sequencing 
revealed that a lung cancer patient did not have any of the standard variants often tested for in 
lung cancer tumors. But he did have an atypical KRAS7 mutation, so the patient was enrolled in 
a clinical trial of an agent that targets the KRAS signaling pathway. 
Abrams also described two innovative trials currently in the planning stage at the NCI’s 
Cancer Therapy Evaluation Program. The first, the Adjuvant Lung Cancer Enrichment Marker 
Identification in Sequencing Trial, which goes by the acronym ALCHEMIST, will be testing 
erlotinib, which targets mutations in the EGFR gene (epidermal growth factor receptor), and 
crizotinib, which targets rearrangements in the ALK gene (anaplastic lymphoma kinase), in 
patients with early-stage lung cancer. Patients with adequately available tissue will have their 
tumors tested for the two types of mutations and will be randomized into the ECOG-ACRIN 
erlotinib trial or the Alliance crizotinib trial.  
 Approximately 8,000 patients will need to be screened to find the 600 to 800 patients 
with mutations needed for the trial. These patients will be followed for 5 years. All EGFR and 
ALK testing will be done in a laboratory certified under the Clinical Laboratory Improvement 
Amendments (CLIA),8 and the rest of the tissue will be sent to investigators for the Cancer 
Genome Atlas, who will conduct genomic sequencing, transcriptome determinations, and 
                                            
7 Human homolog of the Kirsten rat sarcoma viral oncogene. 
8 See http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/index.html. 
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methylation analysis. Patients will consent to be recontacted about the option of doing a second 
biopsy if their cancer recurs to determine subsequent molecular changes in the tumor tissue.  
The second trial, the Master Protocol in Advanced Lung Cancer will have a phase II/III 
basket trial design. Multiple new therapies will be tested simultaneously in patients with non-
small-cell lung cancer, and the study will be a registration trial for the new therapeutics. Patients 
will be assigned to an experimental treatment or a standard-of-care control arm on the basis of 
their molecular profile. If a new drug shows clinical benefit in patient populations that test 
positive for a specific biomarker, then the biomarker test could be given FDA clearance at the 
same time as the drug is being evaluated, Abrams said. Initially, patients will be treated with a 
monotherapy, but combinations that target more than one molecular defect in the tumors could 
conceivably be part of the trial design, he added. 
“We were hoping the NCTN would provide a platform for these kinds of studies and in 
fact changes have occurred that allow this new science to go forward much [more easily] than it 
could have in the past,” Abrams said. “Hopefully, we will have collaborations with our company 
partners that will enable us to have a group of drugs that could target mutations in the same 
trial,” he noted. Miller added that in order for such trials to be successful, companies have to be 
willing to engage in precompetitive collaborations. 
Several participants at the workshop said that although it is encouraging to see the NCTN 
offering innovative trials girded by molecular screening, finding an appropriate clinical trial for a 
patient who has undergone molecular profiling is still a major barrier. “Genomic profiling is 
becoming more readily available, but a bigger obstacle to delivering optimal care to patients is 
actually getting the right drug,” said Richard Schilsky, chief medical officer at ASCO. “Doctors 
are scurrying around trying to find drugs that are suggested by these tests, whether it’s for 
purposes of a clinical trial or for off-label use.” 
Roy Herbst, professor of medicine and pharmacology and chief of medical oncology at 
Yale Cancer Center and Smilow Cancer Hospital, added that in the ALCHEMIST trial, only 
about 15 percent of patients who have their tumors screened will be eligible for treatment in the 
trial. “What’s going to happen with the other 85 percent?” he asked. Abrams responded that he 
hopes to have the NCI’s Cancer Center for Genomics do molecular profiling on the patients not 
eligible for treatment in the ALCHEMIST trial. Bertagnolli added that the Alliance has made a 
commitment to long-term outcome follow-up on all of the patients screened in the study, so there 
will be a mechanism for identifying recurrences in the entire population and an opportunity to 
identify secondary trials for those patients who recur. 
NCI Initiatives 
As Doroshow reported, the NCI has other new initiatives aimed at furthering precision 
medicine and fostering innovative science in the clinical trials it supports, including 
 
 developing an integrated national biospecimen bank for the NCTN as well as a shared 
IT infrastructure to enhance specimen inventories, clinical annotations, and access; 
 developing a common process for requesting biospecimens banked from NCI-
supported clinical trials; 
 revising the request for application (RFA) for the National Specimen Banks for 
NCTN groups (U24 cooperative agreement grants) to include common operating 
procedures for samples collected from the NCTN and other NCI-supported trials. 
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In addition, the NCI initiated its Biomarker, Imaging, and Quality of Life Studies 
Program to ensure that critical correlative studies could be incorporated in a timely manner into 
phase III and large, multi-institutional phase II trials during the process of concept development. 
Between 2008 and 2013, 24 of 88 submitted concepts incorporating integral and integrated 
biomarker, imaging, quality-of-life, and cost-effectiveness analysis studies have been supported, 
for a total commitment of more than $30 million. The supported studies include those assessing 
the relevance of HER2 in esophageal cancer, translocation of 1p:19q in glioma, PET/CT imaging 
of prostate cancer, and OncoType DX in breast cancer.  
The NCI has also restructured its early experimental therapeutics program for phase I and 
II trials. The restructured program has more integration of its cancer biology, translational, and 
clinical components, which are supported by centralized technologies, including clinical data, 
biostatistical, and diagnostics cores. The diagnostics core can provide molecular characterization, 
and the biostatistical core can provide novel and fit-for-purpose trial designs. The early phase 
program is “now a network that is team science–based and has substantially more resources,” 
noted Doroshow.  
However, Comis stressed that “we need a comprehensive strategy for next-generation 
sequencing because right now, we’re all off on our own making deals with companies and 
academic institutions.” Several participants suggested creating a centralized clearinghouse for 
the annotated genetic profiles of patients’ tumors so they can be matched to appropriate clinical 
trials when available or to facilitate use of the data in retrospective studies. 
In such a clearinghouse, “you track everything about the patient—their demographics, 
treatment data—and you do extensive genomic analysis. That way you can learn more about the 
prognosis and the results of standard treatment in small, rare genetic subsets of patients. Another 
advantage is that the patients are prescreened so they can be easily enrolled into clinical trials 
that are developed later,” said Blanke. Patricia Ganz, distinguished university professor at the 
University of California, Los Angeles, Schools of Medicine and Public Health and director of 
cancer prevention and control research at the Jonsson Comprehensive Cancer Center, added a 
plea that any such clearinghouse fully annotate specimens and include information such as 
concomitant medications, health behaviors, environmental exposures, and other relevant host 
factors that might influence the outcome for cancer patients.  
IMPROVING PRIORITIZATION, SELECTION, SUPPORT, AND COMPLETION OF 
TRIALS 
The IOM consensus report emphasized the need for sufficient funding and resources to 
support an effective and efficient national clinical trials system, as well as the need to prioritize 
trial concepts. The IOM recommended that the NCI allocate a larger portion of its research 
portfolio to the NCTN to ensure that it has sufficient resources to achieve its unique mission 
(IOM, 2010b). Although the NCI and NCTN budgets have been flat in recent years (and have 
declined when adjusted for inflation), Doroshow said that the NCI recognizes the need to 
adequately support the system and its investigators. The NCI has also been reorganizing the 
review, selection, and prioritization of NCTN protocols to take into account strengths and gaps in 
trial portfolios, as well as consideration of what trials are best suited for conduct by the NCTN as 
opposed to industry. 
Trial Reimbursements 
The NCI has since increased reimbursement to sites for patients on large phase II studies, 
and also provides additional funding for select phase III trials based on their complexity. 
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However, this necessitates a decrease in the total number of patients enrolled in NCTN trials, 
since overall NCI funding for the program has not increased. The NCI also provides additional 
funding for critical biomarker, imaging, and quality-of-life studies, Doroshow reported, and has 
made changes in the funding model for new RFAs. These changes increase reimbursement for 
high-performing sites that have at least 40 percent accrual to their trials, and increase the core 
resources for genomic correlative studies. 
Identifying Strengths and Gaps in Trial Portfolios 
Scientific Steering Committees (SSCs) appointed by the NCI evaluate and approve trial 
concepts that are judged to be scientifically sound and clinically important. The newly formed 
NCTN Working Group was established to assist the NCI in the prioritization and selection of the 
NCTN clinical trials. This group, which is co-chaired by George Sledge and Robert Diasio, 
William J. and Charles H. Mayo Professor and director of the Mayo Clinic Cancer Center, 
reports back to the NCI’s CTAC.  
The working group is charged with assessing the strength and balance of the active trial 
portfolio within each disease area and across all types of cancer and recommending 
improvements based on emerging scientific opportunities, portfolio strengths and gaps, and high-
priority or evolving clinical needs. The working group will also review and assess the clinical 
trials evaluation process and results by periodically assessing the quality of completed trial 
outcomes, the operational performance of the SSCs, and the efficiency of clinical trials. Another 
task of the working group is to provide strategic advice to enhance NCTN clinical trial 
operations, such as collaboration and timeliness.  
Twenty-eight extramural members from key stakeholder groups comprise the NCTN 
Working Group, including NCTN group chairs and statisticians, Community Clinical Oncology 
Program (CCOP) principal investigators, cancer center directors, steering committee chairs, 
patient advocates, translational scientists, NCI leadership, and Cancer Control Research Base 
principal investigators. “This is the first time that NCI or any group external to NCI has had the 
opportunity to look at the whole trial portfolio. The ability to digest and assimilate the whole 
disease group and to also make comments across the disease entities has never really occurred in 
the history of the Cooperative Group Program or the Clinical Trials Program of NCI,” Diasio 
said. The working group will also consider summary information from other major ongoing trials 
outside of the NCTN for each disease area, such as industry or international trials. 
The working group has developed metrics for evaluating trials that quantify factors such 
as feasibility, clinical importance, scientific contribution, relative cost, patient resources 
required, and appropriateness for the NCTN program (see Box 5).  
The feasibility criterion includes not just time and cost but also accrual difficulty. “It was 
disappointing to see greater accrual in certain studies, but very poor accrual in others. This 
obviously is not a good use of NCI funding or time and it’s important to evaluate upfront the 
feasibility of studies,” Diasio said. For the clinical importance criterion, the working group came 
up with the concept of life-years saved to discern benefit to the patient or the population. 
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BOX 5 
Criteria for Evaluating NCTN Trials 
 
 Feasibility (accrual difficulty, time and cost to implement at sites) 
 Clinical importance (importance of study question relative to state of the science in 
the disease; benefit per patient and for population [e.g., life-years saved]; benefit in 
light of disease context) 
 Scientific contribution (tests important scientific concepts or proof of principle, 
importance of integral or integrated correlative study questions) 
 Relative cost/resources (total number of patients required, length of study [accrual 
and follow-up])  
 Appropriateness for NCTN program (understudied/rare disease, understudied 
populations, trials to optimize a technique, combination trials, international academic 
collaborations, and contribution to public tissue and data resources) 
 
SOURCE: Diasio and Sledge presentation (February 11, 2013). 
 
At the time of the workshop, the working group had evaluated the NCTN trial portfolios 
for patients with leukemia, lymphoma, and gastrointestinal, colorectal, breast, and genitourinary 
cancers. One general finding of the working group was that there was considerable variability in 
the balance of strong and weak studies across disease groups. Although this variability could be 
due to differences in scientific advances or therapeutics developed for each group, there was 
concern that the variability might stem from a lack of standard format for the preparation and 
submission of trial concepts, or from differences in the approach and guidance given by the 
various disease-specific SSCs. 
As an example of the kinds of information gained from such reviews, Diasio noted that 
for breast cancer, the working group found that trials were relatively strong, addressed several 
important questions, were multidisciplinary, and had a good balance between systemic and local-
regional studies. But the working group thought there was still room for improvement and 
recommended smaller, innovative, and more nimble randomized phase II trials, such as 
molecularly driven trials, trials that discover or validate biomarkers, trials aimed at limiting 
toxicity and improving quality of life, and survivorship studies. The working group concluded 
that the breast cancer SSC could provide more strategic guidance for concept selection and for 
developing standards to improve trial design, perhaps by tapping into the resources of other 
groups, such as task forces, working groups, or clinical trial planning meetings.  
Schilsky asked if the working group planned to publicize its assessment of gaps in the 
clinical trials portfolio so clinical investigators are aware of them and can take appropriate steps 
to fill those gaps. Sheila Prindiville, director of the Coordinating Center for Clinical Trials at the 
NCI, responded that any of recommendations or conclusions from the working group will be 
presented at public forums convened by the CTAC. “The information will be available to the 
public,” she said.  
Another workshop participant pointed out that the metric for life-years saved will give 
undue representation to studies done on common rather than rare cancers. “A very tiny advance 
in a really common disease will give you a much bigger pickup of years of life saved than a 
fairly large advance in a rare disease, and certainly rare diseases deserve help, too. So, we 
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wouldn’t want this to be the only metric that’s valuable in terms of looking at these trials,” the 
participant said.  
Another point of discussion centered on the higher cost of innovative trials and how cost 
factors were weighed in the working group reviews of clinical trials. A smaller trial that has 
more robust use of biomarkers may be more costly up front for each patient enrolled, but may be 
more cost-effective than a large trial with thousands of patients followed for long periods of 
time. “Maybe going from the emphasis being on larger phase III studies to more nimble phase II 
studies will allow more of those studies that focus on innovative science to be implemented,” 
said Diasio. Comis noted that this emphasis appeared to be the trend; his analysis of NCTN trials 
found that the number of complex phase II trials is increasing, while the number of phase III 
trials is decreasing. Diasio added that “one of the advantages of having this overview of all the 
trials is to bring the molecular and pathway-driven studies forward for our strong consideration 
at the beginning.” 
Sherman stressed in her presentation that the NCI must give priority to high-quality trials. 
“We have a societal obligation to make sure every trial counts, but most trials use study designs 
incapable of meeting FDA standards for substantial evidence,” she said. She noted that a recent 
study the FDA conducted with Duke University evaluated 96,346 clinical studies registered at 
Clinicaltrials.gov and found that 96 percent had 1,000 or fewer participants and 62 percent had 
less than 100 participants, with the median number of participants per trial being 58 for 
completed trials (Califf et al., 2012). Only 34 percent of the interventional trials were double-
blinded, and 30 percent were not randomized. Compared with other specialties, oncology trials 
were more likely to be single arm (62 percent vs. 24 percent), open label (88 percent vs. 47 
percent), and nonrandomized (64 percent vs. 23 percent) (Hirsch et al., 2013). 
Reflecting on these findings, Sherman said “The vast majority of trials done in this 
country are small and uninformative. We’re almost definitely not spending our resources as 
wisely as we should and we as a nation have to think about how we can change that trend. The 
worst thing to do is expose a person to a test agent and not have that count. Quantity is less 
important than quality and, less obviously, it’s drowning out the useful information by creating 
too much noise.” 
Lessons from the National Clinical Trials System in the United Kingdom 
Richard Kaplan, associate director of the UK National Cancer Research Network 
(NCRN) and UK Clinical Research Network and senior scientist at the Medical Research 
Council Clinical Trials Unit, described how the UK NCRN operates and how it differs from the 
U.S. NCTN. He also noted relevant strengths and disadvantages of the UK system compared 
with the NCTN. 
The NCRN is a single national system for cooperative phase II and III cancer clinical 
trials in the United Kingdom. The NCRN manages research staff in 32 regions, is tightly linked 
to regional cancer treatment organizations, and supports research nurses and data managers 
throughout the National Health Service (NHS). The UK National Cancer Research Institute 
(NCRI) is a partnership of government and charity funders who jointly set policies and research 
priorities and coordinate needed resources for cancer research. Cancer Research UK (CRUK) is 
the largest UK cancer charity and largest cancer research funder in Europe. Clinical Studies 
Groups (CSGs) are UK-wide single-disease committees responsible for developing studies and 
overseeing their research portfolios. Clinical Trials Units (CTUs) are equivalent to the 
coordinating and data centers in the U.S. NCTN.  
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In the United Kingdom, virtually all of the clinical costs for patients in cancer clinical 
trials are covered by the NHS. Network infrastructure is funded by the National Institute of 
Health Research (NIHR), the UK equivalent of the U.S. National Institutes of Health (NIH). 
Some CTUs receive core funding via competitive peer review every 5 years, but CSGs only have 
a small budget to cover meeting expenses. Each trial must achieve peer-reviewed funding from 
the NIHR, the CRUK, or other funders. Such funding covers CTU central costs and clinical costs 
other than those covered by the NHS. Increasingly, industry has funded UK clinical trials, 
Kaplan noted. “Half of all big trials have some form of industry support, which makes a big 
difference in making them go fast,” he said.  
CSGs are the primary venue in which new proposals for clinical trials are developed in 
specific disease areas. Membership in these groups rotates and there is a competitive national 
appointment process for new chairs and members. In addition to clinical and scientific members, 
CSGs include patient and funding-body representatives. The CSGs’ main objectives are to 
oversee existing studies, consider new research questions and develop new proposals, and 
provide expert advice. They also interface with industry partners for consultation about the 
feasibility of clinical trials and oversee specimen resources.  
Anyone outside of a CSG can apply for a grant to do a trial, which is conducted with a 
CTU, Kaplan noted, but “even if these studies arise from somebody who’s not on one of these 
CSGs, they will be fed into the CSG, where the proposal will be discussed and refined and then 
put through as a sort of joint proposal.” Every CSG publishes its trials portfolio on the Internet 
because all of the studies are potentially open to any site in the country qualified to perform 
them, he added. All CSGs undergo progress reviews by their peers, including representatives 
from North America and Europe, every 3 years. These external peers review the research 
portfolio, but do not do in-depth reviews of individual current trials, and mainly focus on the 
membership, activity, scope, future plans, and strategic direction of the CSG.  
“Funders are careful to look for whether research questions are considered important to 
external peer reviewers,” Kaplan said. He added that funders also “work hard to prevent too 
many competing large-scale trials and to decide whether the extra capacity is there for a second 
trial on top of one that’s already in place. The different funders coordinate behind the scenes 
when they receive new applications to make sure that they’re not working too much at cross 
purposes.” 
Each regional network selects the trials it wants to support, and any trial is available as 
long as the site is qualified to run it. “The smaller community hospitals tend to participate in the 
non-interventional trials for the most part, but they do refer lots of patients elsewhere for the 
interventional trials,” Kaplan said. The individual trials have recently been required to meet 
particular time and target metrics, and some regional network funding has been explicitly linked 
to actual activity. “League tables” that compare performance are compiled and made public.  
In 2001, when the UK clinical trials system was restructured and the NCRN was 
established, a major goal was to increase patient accrual to cancer clinical trials. Accrual grew 
from about 4 percent of all cancer patients in 2001 to 23 percent in 2011. Part of the increase is 
due to the availability of more non-interventional, observational, and other nonrandomized 
studies conducted in community hospitals. Many of these sites had not previously done clinical 
research and undertook such studies as a way to gain experience and build up staff in order to 
develop the capability to do interventional trials in the future, according to Kaplan. But even in 
randomized trials, accrual is about 7.5 percent of patients diagnosed, he said. That percentage 
translates to about 19,000 patients enrolled each year, about the same number of patients enrolled 
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in the U.S. NCTN trials, despite the United Kingdom’s smaller population of 50 million, Kaplan 
noted. 
The NHS’s commitment to clinical research also encourages physicians to enroll their 
patients in clinical trials, according to Kaplan. During its annual performance reviews, the NHS 
assesses physicians’ participation in the clinical trials available in their network. Peer 
expectations also play a role, he said. “If you are an oncologist who doesn’t participate in clinical 
trials that are available, it just doesn’t look good. You lose face with not only your supervisors 
but with your peers,” Kaplan said. 
He said the most important driver of success for the whole system appeared to be “the 
new research staff they put in place, who were very carefully ring-fenced. The hospitals were not 
allowed to use research nurses for ordinary cancer care delivery.” Kaplan also noted that the size 
of the United Kingdom favors nationwide collaboration. In most cases, the country is just big 
enough to do independent large-scale trials but not big enough to do too many competing trials in 
most diseases. 
Some of the disadvantages of the UK system noted by Kaplan include metrics that 
discourage clinical trials on rare diseases; the increased burden of following patients on prior 
trials, which interferes with the ability to start new trials; local networks tending to activate 
“easy” studies because some of the most important studies are the most work-intensive; and a 
complex system for approvals that delays trial activation.  
Kaplan noted that the major cultural difference between the UK cancer research system 
and the U.S. system is that cancer research in the United Kingdom is viewed as being part of the 
health care system, rather than separate from it (as in the United States). In response to a 
question from a workshop participant about the ability of the UK system to support genomic and 
other molecular studies on cancer patients, Kaplan responded that the CRUK has proposed a 
major initiative to build such research capacity into the system, starting with major cancer 
centers that will eventually characterize every patient treated. There also is a UK Department of 
Health initiative to achieve the same objective. “It’s clearly seen as a priority to all of the 
funders,” he said.  
In response to a question from Pazdur about the type of cancer trials conducted in the 
United Kingdom, Kaplan noted that “much of the thrust of the CSG has been new drug 
development, with more than half of the trials being phase III trials,” although he added that the 
number of phase II trials is increasing. Herbst asked how biomarker tests for patient stratification 
are paid for in UK cancer trials. Kaplan replied that research funders, including the arm of the 
government that funds the trials themselves, are currently paying for this resource. He noted that 
a few central labs will be handling specimens and doing molecular profiling for a large colorectal 
cancer study he is involved in, and although it may not be cost-effective to do such tests yet, 
“we’re simultaneously trying to build the systems for it to become so.”  
Studies More Appropriate for NCTN Than Industry 
There was extensive discussion about which studies are more appropriate for the NCTN, 
vs. industry, to undertake. Doroshow noted that industry is not likely to do trials of agents for 
more than one histological type of cancer, so these types of trials are more appropriate for the 
NCTN. “So many of the advances in cancer medicine and clinical trials research have been 
multidisciplinary in nature and it’s not in industry’s business model to do those kinds of studies,” 
he said. He also quoted a former industry scientist, who said, “Even Johnson and Johnson, with 
all of its budget, doesn’t have access to the kind of cancer biology that the NCI supports, so if 
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you’re going to change your system, change it in a way that allows you to optimally use that 
tumor biology and help bring that [knowledge] into the clinic.” 
Pazdur stressed the notion that the NCTN should not do trials that can be done by 
industry, given that publicly funded resources support these trials. Blanke agreed, saying, “The 
cooperative groups have to do the research that no one else can or will do. In the old days, it was 
the large-scale phase III trials, but now it’s the trials on rare diseases or subsets of the common 
diseases. Harnessing multiple drug companies to work together is not going to come from 
industry voluntarily. Industry is also not likely to harness our basic scientists in drug 
development and conduct multidisciplinary or multimodality trials.”  
But Comis said, “I don’t think we should be pigeonholed into rare tumors. I would much 
rather be pigeonholed to a rare biologic process, but not necessarily rare tumors.” He added, “We 
can be on the forefront of integrating biology into our studies and are already doing that. We 
have multiple studies that cross diseases, so I think we have that platform.”  
But Adamson made a plea for prioritizing trials of childhood cancers, most of which are 
rare. “We do studies in the Children’s Oncology Group [COG] on diseases with an incidence in 
this country of less than 100 children a year. We need to be able to decide what is the highest 
priority at any given time because otherwise, we’re going to run out of patients, and by ‘we’ I 
mean parent patient advocates and specialists throughout the field,” he said. He added that the 
return on investment from NCI funding for COG and the cooperative group program is quite 
remarkable. 
Adamson noted that in the 1950s, the 5-year survival rate for childhood cancers was 10 
percent and now it is 80 percent. “That improvement was made entirely with NCI resources,” he 
said. Now, more than 90 percent of pediatric cancer patients in the United States receive 
treatment at COG sites and more than half are enrolled in COG trials. Still, cancer remains a 
leading cause of death in children, “so the work is just really beginning,” Adamson said. “I don’t 
think there’s any entity other than the cooperative groups that can ultimately act hand-in-hand 
with patients, parents, and families, as well as industry in setting the priorities,” he concluded.  
Comis agreed with Adamson about the need for the NCTN to conduct studies on children 
with cancer. “Having the NCI prioritize pediatric studies earlier than companies did has been 
very helpful. Other kinds of studies that maybe industry can do but cooperative groups can do 
even better are novel combinations, especially when the novel agents are premarket compounds 
from different companies.” He added that because there are multiple mutations that often are not 
discerned by a typical companion diagnostic test developed by industry, “We need to have a 
broad-based approach to the biology of these cancers, and instead of doing a registration trial, 
lead the way towards what the FDA, the payer community, and the research community need to 
do in order to do cutting-edge research. The role of the groups is probably more important now 
than it ever was. The best thing for patients is what we should do.”  
Nancy Roach, president of the Colorectal Cancer Coalition, pointed out that the NCTN’s 
ability to share data “makes it a lot easier to run multicenter trials,” as opposed to industry. She 
added that the NCTN should conduct biomarker-driven trials that clarify which drugs work for 
which molecular subtypes of tumors, now that more patients are getting their tumors sequenced. 
Otherwise, their doctors will give them a drug off-label, and information about the 
appropriateness of that drug for their tumors will be lost. Curran agreed, noting that the 
cooperative groups have tested a number of therapies for off-label use in randomized trials that 
showed a lack of benefit; as a result, these therapies are no longer offered for those indications. 
“This improved cost-effectiveness [of treatment] and lowered toxicity,” he said. Curran 
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advocated for the NCTN to continue to do such off-label use studies and comparative-
effectiveness research, which industry is less inclined to pursue.  
INCENTIVIZING PATIENT AND PHYSICIAN PARTICIPATION 
One of the IOM goals for the NCTN was to incentivize the participation of both patients 
and physicians in clinical trials by supporting clinical investigators and covering the cost of 
patient care in clinical trials. The IOM also recommended that the NCI, cooperative groups, and 
physicians should take steps to increase the diversity of patient accrual.  
Boosting Patient Accruals 
 Abrams said that the number of cancer patients enrolled in NCTN trials has declined in 
recent years, to about 20,000 per year. Abrams reiterated that over the past 10 years, the United 
Kingdom was able to substantially boost the rate of patient participation in clinical trials through 
financial reimbursements. “We have a different system here, but if patient advocates were 
looking for a way to truly increase the uptake in clinical trials, that would certainly be a cause 
worth fighting for,” he said.  
Roach suggested that there might be more patient enrollment if more clinical trials 
assessed quality-of-life issues important to patients, such as which cancer treatments cause the 
least amount of neuropathy. “Let’s not throw out the boring but high-impact studies, and do only 
the really cool science,” she said. She also suggested conducting a pilot project to see if 
reimbursing oncologists for the time it takes to inform their patients about clinical trials and 
covering other trial-related expenses could increase patient accrual in trials. 
Recent improvements to the NCTN consent form template may facilitate patient accruals. 
The new template, which will be implemented in 2013, is shorter and less complex. The risks are 
easier to understand and are presented in a way that is meaningful to patients. In addition, 
different tables of risks are presented for the experimental vs. standard arms, which are grouped 
by regimen. Risks are described in lay terms and listed according to the body system affected.  
Doroshow added that the NCI works with patient advocates in trial concept development 
and accrual planning, along with the cooperative groups, disease SSCs, and the Patient Advocate 
Steering Committee. He also stressed that the NCI tries to enhance trial participant diversity 
through the Minority-Based CCOPs, the Patient Navigator Research Program, and other NCI 
programs. 
Speaking from the patient perspective, Patrick Gavin, president of Patrick Gavin R.Ph. 
Consulting LLC, stressed that patient involvement in clinical trial development is key to 
enrolling the large number of patients needed to conduct clinical trials of innovative targeted 
interventions. “We as patients have the unique ability to be able to look at a proposed piece of 
research and tell you if a patient would be willing to participate in your experiment while we’re 
trying to stay alive,” he said.  
For example, he said one proposed study reviewed by a patient advocate gave patients the 
option of being randomized to one of two treatments already available on the market. As Gavin 
described it, “The advocate asked the principal investigator, ‘Why would a patient or their 
oncologist choose to be on this trial with such totally different arms, when both treatment options 
exist now and he would not be bound by the randomized coin flip if he had them outside of a 
trial?’” This comment led to the trial being restructured, Gavin reported, adding that without 
input from the patient advocate, “the trial would have likely gone ahead and huge investments 
would have been wasted because the trial would not have accrued because local oncologists and 
patients would not have bought into it.” 
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Gavin stressed that the large numbers of patients treated in community settings are 
especially needed for precision medicine studies, adding,  
 
We have to engage the broadest possible patient community in order to make clinical 
trials and personalized medicine possible. The nature of personalized medicine will not 
allow for a few thousand patients involved in answering a single question, but tens of 
thousands of patients answering thousands of questions. That patient community doesn’t 
exist if we only look to the large cancer centers. We have to be able to reach out to every 
hospital and other settings where patients live and convince them they need to participate 
in clinical trials if we are to achieve [real progress]. Patient advocates can make these 
essential partnerships with patients a reality. 
 
Gavin noted that there are a number of things patient advocates can do to help boost 
accruals to clinical trials, including 
 
 developing strategies that accelerate study development, activation, accrual, 
participation, and reporting; 
 ensuring selection of trials that affect clinical outcomes for people with cancer; 
 educating the public on the availability of clinical trials as a treatment option; 
 developing patient-centered materials to help treating physicians discuss trials with 
patients; and 
 publishing and disseminating clinical trial results in plain language. 
 
“Use our patients advocate networks in addition to the National Clinical Trials Network,” Gavin 
concluded. “We can help you build effective trials that patients will want to join and their 
oncologists will want to recommend—we can help you get the message out. Involve us as early 
in the development process as possible,” he said. 
Schilsky asked Gavin how patients can engage their oncologists to ensure that they 
discuss clinical trial opportunities. Gavin responded that patient advocates advise patients to talk 
to their oncologists about options for a clinical trial as a possible treatment option and encourage 
them to “do their homework” beforehand by exploring websites that list those trials. 
Increasing Physician Participation 
Participants at the workshop also voiced concerns about a decline in the number of 
physicians willing to engage in clinical trials. Several speakers said that more mentoring and 
funding for young investigators are needed to maintain a critical mass of clinical investigators.  
Comis noted several fellowship award programs ECOG-ACRIN has designed to attract 
new investigators, including the Young Investigator Awards. Eleven out of 15 recipients of this 
award during the past 15 years have entered senior positions in ECOG-ACRIN. All of these 
awards were supported by ECOG-ACRIN’s foundation, not federal funds, Comis said. He added 
that ECOG-ACRIN plans to develop a mentorship committee to formalize the fellowship 
awards. “Each committee chair is paying attention to bringing young investigators in, but I don’t 
think that’s enough, so we’re going to formalize that program,” he said.  
Blanke added that SWOG also has funding opportunities for young investigators, as well 
as a course in which participants are flown to Seattle to learn from “the best of SWOG.” 
Participants are expected to develop a clinical trial protocol by the end of the course. “They not 
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only get teaching, but a sense of excitement, and a large percentage of them move forward,” 
Blanke said. He added that SWOG is starting a formal mentorship program that will pair mid-
level investigators with young investigators in each clinical trial. SWOG is also creating more 
leadership opportunities in the subcommittees for each trial. “That way, young investigators can 
engage in the governance and scientific direction of the group as well,” Blanke said. 
Roach added that young investigators in the academic setting should be better rewarded 
for pursuing clinical research and engaging in collaborative studies for which they may not 
receive much authorship recognition. Michael Caliguiri, CEO of the James Cancer Hospital and 
Solove Research Institute, director of the Comprehensive Cancer Center, and professor of 
internal medical at the College of Medicine at Ohio State University, agreed. He noted that “the 
ability to convince department chairs and deans at academic institutions to be more tolerant of 
the extramural situation and clinical research and to recognize accomplishments that aren’t 
traditionally measured has been a challenge. We need to come together and set some new rules 
in these changing times about what we regard as worthy of promotion, because that’s ultimately 
what keeps many of our young investigators in the game.” Doroshow pointed out that since 
2009, the NCI has been providing Clinical Investigator Team Leadership Awards to promote 
collaborative science and to recognize outstanding clinical investigators.  
Adamson added that young investigators could also be encouraged by a more efficient 
system that results in faster decisions, saying that 
 
the most disheartening thing for young investigators is to invest 1 or 2 years of their 
career developing a clinical protocol that doesn’t get approved. We need a system where 
we can fail early [rather than later]. If we don’t solve that, it’s going to be hard to sit 
across the table from any young investigator and tell them why they should be involved. 
It’s one thing to invest 4, 5, or 6 months of an academic career and have an idea die. It’s 
very different to do it for 2-plus years, and then have to go back to the drawing board. I 
don’t think NCTN has addressed this.  
Tapping Community Practices 
Worta McCaskill-Stevens, chief of the Community Oncology and Prevention Trials 
Research Group and head of the Breast Cancer Prevention and Minority-Based CCOPs in the 
Division of Cancer Prevention at the NIH, expanded on what has been done recently to increase 
patient diversity and the involvement of community practices in NCTN clinical trials. She began 
by describing recent changes affecting research conducted by community practices. She noted 
that due to financial pressures, such practices are increasingly merging and being acquired by 
hospitals. Consequently, investigators are “having to negotiate and see affirmation of the role of 
clinical trials within those systems,” she said. Stephen Grubbs, principal investigator of the 
Delaware Community Clinical Oncology Program and managing partner at Medical Oncology 
Hematology Consultants, PA, said these mergers are a major problem in the current era of tight 
budgets because hospital administrators often are not willing to devote resources to cancer 
research.  
McCaskill-Stevens also noted the increasing role of molecular-based cancer care, and 
stressed that “the best laboratory in which care systems can be evaluated are the community 
settings,” where the majority of cancer patients are treated. Grubbs concurred, noting that 
historically, the majority of accruals for the cooperative group program have come from 
community-based practices. He said it is important to prepare these practices for the shift in 
emphasis within the NCTN to biomarker-driven phase II trials, “Without the community 
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programs, [those trials] aren’t going to get done fast enough, so we have to make sure that 
program is strong as we do more phase II trials,” he said.  
The CCOPs are “working to try to educate the advocacy community as well as other 
populations about biospecimens,” said McCaskill-Stevens. The program is evaluating 
infrastructure requirements at the local level for collecting and processing biospecimens, and 
hopes to strengthen that infrastructure accordingly by ensuring the availability of pathologists 
and other necessary personnel.  
But Benz pointed out that reimbursement is lacking for tasks related to acquiring and 
testing specimens for patients in clinical trials, which go beyond routine clinical management. 
“Something needs to be built into the reimbursement system because the mechanisms for 
funding that in a community setting are almost nonexistent unless they have some formal 
collaborative relationship with a big cancer center, which immediately shrinks down the 
number,” he said.  
Grubbs added that not only is a reimbursement code required for acquiring and testing 
biospecimens, but that code also has to be recognized by the payer. A reimbursement code is also 
required to reimburse physicians for the time they spend offering and explaining clinical trial 
options to patients, he said. “Even if the patient doesn’t actually go on a trial, clinicians still can 
spend a tremendous amount of time reviewing the trial with the patient and their family,” Grubbs 
said. Doroshow said that the NCI continues to work with the NIH and other federal agencies to 
help define and shape national policy on clinical trials and reimbursement, as well as to educate 
patients and payers regarding the benefit of clinical trials. 
McCaskill-Stevens reported that at the end of 2012, the NCI integrated the CCOPs, the 
Minority-Based CCOPs, and the NCI Community Cancer Centers Program (NCCCP), along 
with the research bases for those programs, into a new program called the NCI Community 
Oncology Research Program (NCORP). She said this consolidated program will expand the 
research scope in the community setting to include not just clinical trials, but also research on 
cancer disparities and cancer care delivery (NCI, 2012). McCaskill-Stevens noted that NCORP 
representatives serve on CTAC. The integral components of NCORP are the community-based 
oncology practices. These practices have a variety of research capacities linked to the NCTN and 
are provided with the support needed to participate in a collaborative research network (see 
Figure 4). 
McCaskill-Stevens said that NCORP is a public–private partnership with a commitment 
to co-investment. Eligibility for NCORP community sites is based on the capacity to participate 
in cancer research, including 
 
 clinical research experience (clinical trial accrual); 
 cancer care delivery research infrastructure; 
 available study populations; and 
 senior leadership/organizational support.  
Eligible community practices that participate in NCTN clinical trials have been supported with 
3-year grants, but NCORP recently proposed extending those grants to 5 years in recognition of 
the difficulty the sites had in activating the initial grants and the challenge of preparing for 
another competitive renewal after only 3 years, said McCaskill-Stevens. 
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FIGURE 4 2013 site map for the NCI Community Oncology Research Program (NCORP). Circles 
represent NCI Community Cancer Centers Program (NCCCP) sites; squares represent Community 
Clinical Oncology Program (CCOP) sites, and triangles represent minority-based CCOP sites. The darker 
shaded states are those that have NCCCP sites. 
SOURCE: McCaskill-Stevens presentation (February 12, 2013). 
 
NCORP instituted a number of changes aimed at boosting patient accruals from 
community practices. In addition to transitioning to the use of the new, 24/7, Web-based 
oncology patient enrollment information technology of the NCTN, NCORP is developing a 
single portal of entry for institutions rostering with the NCTN that should improve the efficiency 
of the current system, which requires rostering with multiple networks. There are also ongoing 
discussions about how investigators can use the NCI’s Central IRB for primary review of cancer 
control and prevention studies run by NCORP. 
NCORP has also been promoting the participation of underserved populations and 
incorporating disparities research questions into clinical trials and cancer care delivery research. 
Grubbs noted the diversity of different underserved communities, from rural populations and 
Native Americans to African Americans and Hispanics. “Every community has a different 
underserved community to deal with. There’s not one program that can encompass them all, and 
plenty of opportunities,” he said. But there is a lack of research on how best to enhance research 
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participation and improve health care for underserved communities. Grubbs said he supports 
cancer care delivery research, but is concerned about inadequate infrastructure and resources to 
do such research in the community setting. Centralized databases, such as those of the Centers 
for Medicare & Medicaid Services and state databases for Medicare or Medicaid claims, might 
aid in such research, he suggested. 
Robin Zon, principal investigator of the Northern Indiana Cancer Research Consortium 
CCOP and vice president at Michiana Hematology-Oncology, PC, said that some physicians in 
competitive practices may not be willing to share their data unless they are de-identified and 
confidential. These physicians are already so time-crunched that “we don’t want to stress them 
by asking for more data or other information about their health care practices,” Zon said. She 
noted that clinical research in community practices is optional, so burdening physicians with 
these requests may lead them to opt out of participating in it. “We need to make things easy for 
them,” she concluded.  
Grubbs noted that in order to take advantage of the improved IT components of the 
NCTN, including its Web-based enrollment system, physicians in community practices need to 
have compatible electronic medical records. “But we’re finding that the hospital practices and 
private practices use different electronic health record systems that don’t talk to each other,” he 
said. Having a compatible electronic records system will require financial resources that many 
private practices do not have, Grubbs cautioned.  
Zon also raised the issue of pay-for-performance measures, which are increasingly 
common among institutions and health insurers and might deter physicians from spending time 
on research activities. She added that the Patient Protection and Affordable Care Act does 
mandate coverage for clinical trial participation, but “it’s not really clear to me how to interpret 
that. We need to lobby to make sure such coverage becomes absolutely imperative with no 
grandfathering and other exceptions,” she stressed.  
REGULATORY ISSUES  
Under the broad goal of improving the speed and efficiency of clinical trials, the IOM 
consensus report included a recommendation for a trans-agency effort to streamline and 
harmonize government oversight and regulation of cancer clinical trials (IOM, 2010). Another 
IOM recommendation specified that the NCI, in cooperation with other agencies, should 
establish a consistent, dynamic process to oversee the development of national, unified standards 
as needed for oncology research. Consequently, a number of regulatory issues were discussed at 
the workshop, including regulatory oversight of the diagnostic tests used in clinical trials and 
trials focused on small subsets of cancer patients, as well as international differences in 
regulations and how to harmonize them. Speakers also addressed how to avoid bias when 
assessing treatment response in clinical trials, and under what circumstances progression-free 
survival is an acceptable endpoint. 
Doroshow noted that there is now a coordinated process for the development and review 
of trials under the FDA Special Protocol Assessment, and the NCI also established an 
interagency agreement with the FDA for rapid review of approved NCTN phase III treatment 
trials at the concept stage. He added that the NCI has been working with the FDA to coordinate 
early review of biomarker tests, as well as to facilitate the development of companion 
diagnostics and incorporation of genomic tests into clinical trials. 
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Regulation of Biomarker Tests 
John Jessup, chief of the Diagnostics Evaluation Branch in the Division of Cancer 
Treatment and Diagnosis at the NCI, pointed out that a number of reports in recent years have 
highlighted the risks for patients posed by new and poorly validated diagnostics. “Investigators 
want to use markers, but they oftentimes have not understood the rigors of clinical assay 
development,” he said. Jessup added that in late 2010, the FDA Office of In Vitro Devices began 
to enforce its oversight authority for the safety of diagnostics used for medical decision making 
in clinical trials.  
Biomarker tests used for medical decision making, even within a clinical trial, are 
required by law to be performed in a CLIA-certified laboratory. These tests include companion 
diagnostics, which are used in conjunction with targeted therapies, as well as molecular tests that 
stratify risk of disease recurrence or adverse reaction to treatment or those that indicate proper 
dose. Biomarker tests used solely for research purposes, including prognostic, predictive, and 
pharmacogenomics markers, do not need to be performed in CLIA-certified laboratories.  
According to the FDA, if a biomarker test has the potential to “present serious risk to the 
health, safety or welfare of a research subject,” clinical investigators must get an FDA 
Investigational Device Exemption (IDE) in order to use the test in their studies and must collect 
safety and effectiveness data. However, Jessup noted, “serious risk is not well defined or 
quantified,” despite two FDA guidances that mention it (FDA, 2006, 2012d).  
To obtain an IDE, a principal investigator is expected to document the analytical 
performance of the assay, including its accuracy, reproducibility, and precision, and how these 
characteristics translate into false positives or negatives. This information is used to demonstrate 
to the FDA that the risk of using the device (i.e., biomarker test) is less than the potential 
treatment benefit. “This means that once an assay is going to be used in a trial, even at the 
concept stage, it is important to be submitting information about the validity and performance of 
that assay as soon as possible,” Jessup stressed. He added that the NCI Cancer Diagnosis 
Program will assist in this process by providing templates for documentation of assay 
performance for immunohistochemistry, fluorescence in situ hybridization, and somatic mutation 
detection. But Jessup also cautioned that “a lot of the tests that seem extremely exciting may not 
be reproducible or accurate.”  
Once assay performance data has been gathered, there is a formal pre-submission 
program that includes meetings with FDA staff. Jessup noted that a recent draft guidance on pre-
submission for devices outlines current FDA recommendations about clinical assay development 
and provides information on how to contact the appropriate FDA offices (FDA, 2012a). If the 
results of an assay are not used in treatment decisions in a clinical trial, the test does not pose 
significant risk and an IDE is not required, Jessup explained. However, biomarker tests used for 
eligibility criteria, treatment assignment, or dose modification may require a pre-submission IDE 
review.  
In summary, Jessup suggested that investigators include in their trial protocols a section 
that documents the risk of false positive or false negative assay results and the potential 
consequences of false results in the context of the disease. Investigators should also indicate 
whether they think an IND (Investigational New Drug) application or IDE is required. Jessup 
added that the potential consequences of false results from biomarker assays should be described 
for patients in the informed consent documents. “The FDA wants to know exactly what patients 
are being told about the markers and the consequences of the assay results,” he said. He 
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concluded that “principal investigators, assay developers and performers, and sponsors need to 
collaborate and partner closely.”  
Garraway noted that “just because something is done in a CLIA lab doesn’t automatically 
mean that it’s done with high quality. It just means that it’s done the exact same way every single 
time.” Garraway is part of consortium that is currently trying to define appropriate metrics for 
sequencing standards that could cut across various types of platforms and approaches and offer 
objective performance comparators (National Human Genome Research Institute, 2013). 
Solit stressed that biomarker validity is more important for late-stage clinical trials. He 
suggested that there should be a lower bar for biomarkers used in early-stage clinical trials. 
“Oftentimes, patients have no other treatment options. I don’t see any risks in the trials that we’re 
running in advanced metastatic cancer patients, who typically have a life expectancy of less than 
a year,” he said. But Miller countered that “the field was set back substantially by 
misinterpretation of EGFR assays, so even if multiple platforms are contemplated, there should 
be a common playing field with minimal criteria.”  
Comis noted that testing a companion diagnostic concurrently with an intervention in a 
registration trial can be limiting as it “locks onto a specific assay, when the whole dynamics of 
understanding mutations and their interactions” is continually evolving. “It can inhibit the kinds 
of clinical trials we want to do, in which the biology, especially the mutations, drives the 
treatments tested in patients,” Comis said.  
Capdeville agreed, noting that by the time a drug and companion diagnostic are 
approved, the field often has changed markedly, with newer genetic techniques coming to the 
fore. “Still, we have to start at some point when we do a clinical study, so we need informed 
consent that is written carefully to allow the flexibility to not only work with the assay you have 
at the start of the study, but to be open to some more exploratory work as better technology 
becomes available. It is critical that you have the ability to store samples for future testing,” he 
stressed. 
Pazdur said that the label for a companion diagnostic merely states that it is FDA-
approved. “Inherent in that is the belief that these tests will change over time and that’s why 
there will be bridging studies that are done that compare one in vitro diagnostic to another in 
vitro diagnostic. I don’t think anyone in the FDA believes that this is a static field. The grand 
daddy of in vitro diagnostics is estrogen and progesterone testing, and that has evolved since the 
mid-1970s due to various bridging studies that compared different technologies,” Pazdur said. 
But Mendelsohn responded that there is a lag in implementing improvements to 
companion diagnostic tests because the assays are paired to specific treatments. “When you 
check for KRAS, you have to use the approved paired assay, which we all know misses some 
mutations in KRAS, if you want to get paid for giving the drug. So, your philosophy hasn’t hit 
the practice of medicine yet, unfortunately,” he said.  
Regulatory Oversight for Trials of Small Subsets of Cancer Patients 
Participants discussed the appropriate regulatory oversight for trials of small subsets of 
cancer patients. Pazdur noted that “when there’s a very small population of patients that could 
benefit from a drug, it would be nearly impossible to conduct a randomized study. Instead, we 
would take a look at the response rate and the toxicities of the drug,” and if the benefits outweigh 
the risks, the drug would be approved for the indication, he said.  
Pazdur added that “one has to balance out what you’re seeing in this small subgroup vs. 
what you’re seeing with existing therapies. If you have a drug that has an exceedingly high 
response rate, we would take a very kind look at that, and proceed with an accelerated approval 
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for that indication. For rare diseases in general we have taken a very liberal policy, even when it 
comes to the characterization of safety in that subgroup because it simply cannot be shown.”  
Less Burdensome Reporting 
Many clinical trials conducted by the NCTN assess secondary indications for approved 
drugs. Schilsky reported that a retrospective study conducted by ASCO in collaboration with 
industry used cancer clinical trial data to assess whether much of the collection and reporting of 
adverse events for drugs being tested for supplemental indications is necessary. A recent draft 
guidance from FDA (2012c) may help improve the efficiency of such trials by explicitly 
encouraging new and less burdensome ways of gathering and reporting adverse events and 
concomitant medications.  
“Sometimes important safety signals can be obscured by all the additional information 
we’re required to report that oftentimes is not terribly informative,” Schilsky said. “We want to 
reduce the data collection burden on the clinical trials system so we can enhance physician 
participation, because one of the big obstacles we hear from doctors all the time is that there is so 
much paperwork involved in doing clinical trials that it’s just not worth the trouble,” Schilsky 
added. 
The ASCO study re-analyzed multiple clinical trial toxicity databases and examined 
various sampling methods to determine if a more streamlined and “optimized” approach to data 
collection would provide sufficient safety data to support supplemental applications. This study 
found that capturing excess Grade 1 or 2 adverse events did not appear to add to the known 
safety profile, and that the probability of missing a previously unrecognized, clinically 
significant Grade 3 or 4 adverse event was low when the optimized data collection approach was 
used. In addition, review of concomitant medication databases from six trials demonstrated that 
no new information was gained from the summary tabulations required to be listed in the 
application for a supplementary new drug or biologic indication. 
The resultant white paper (Abrams et al., 2009) recommended that for future 
supplemental trials with the appropriate qualifications, researchers need not collect 
 
 Grade 1 or 2 adverse events (already known) 
 Grade 3 or 4 events in all patients 
 Stop/start dates for AEs except by cycle 
 Concomitant medications, unless they are likely to interact with the drug being given, 
have an antitumor effect, or meet a specific objective of the trial (e.g., are integral to a 
health economics/costing study) 
 
The analysis also indicated that a subsample of about 400 patients provided adequate probability 
of detecting adverse events with at least a 3 percent excess toxicity. The authors suggested that 
the FDA should put forth a detailed guidance document with clear directives on data collection 
requirements for concomitant medications and adverse events for trials of supplementary drug 
indications. 
The FDA responded by issuing a new draft guidance in February 2012 stating that 
targeted safety data collection akin to what was done in the ASCO study may be appropriate 
when the safety profile of the drug is already well characterized from prior studies, with adverse 
event type and frequency being similar across multiple studies, and when the expected adverse 
event rates in study population are likely to be similar to what was found in previous studies. In 
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addition, the FDA specified that targeted safety data collection may be appropriate for 
postmarketing studies for new indications, studies required to meet postmarketing requirements, 
and large outcome studies.  
“We’re making great progress here. We have strong data that supports the notion that for 
supplemental applications there can be substantial reduction in the amounts of safety data 
collected without missing any important safety signals. I think that’s been acknowledged in the 
recent FDA draft guidance on this topic,” said Schilsky.  
Sherman, of the FDA, pointed out during her presentation that the purpose of the draft 
FDA guidance is to help clinical trial sponsors determine the amount and types of safety data that 
should be collected during late-stage premarket and post-approval clinical investigations. She 
said this draft guidance makes clear that sponsors can use a variety of approaches to fulfill their 
monitoring responsibilities, and that sponsors may request different reporting formats or 
frequencies for adverse event reporting either by describing the method in the protocol or by 
requesting a waiver. Either way, Sherman stressed, alternative reporting must be agreed to by the 
FDA in advance of the trial launch. “Before your plan is put into place, come talk to us and make 
sure that everyone is happy,” she said. 
Roychowdhury was more cautious about modifying adverse event reporting. He noted 
that given the new mechanisms of action of many new cancer drugs, “I’m a little bit hesitant to 
have guidances that even for supplemental indications are going to reduce the surveillance on 
even Grade 1 and 2 toxicities.” He added that although collecting less safety data for clinical 
trials testing new indications for well-known cancer drugs may be appropriate, large companies 
that sponsor such trials have general SOPs for all types of therapeutic areas. “Unless the FDA 
and EMA come up with very clear guidances that separate oncology clinical trials from the rest, 
we will continue to see collection of safety data that may look to you as being superfluous and 
overcautious,” he said.   
 Schilsky acknowledged concerns about some drugs moving into clinical use with limited 
safety data assessment. “The sponsor and the regulatory agencies should sit down and decide 
what is sensible data collection given the patient population being studied, the pharmacological 
class of agent, the known safety profile of the drug and the objectives of the trial,” he said. 
Progression-Free Survival Endpoints and Bias 
Speakers and participants also explored how to avoid bias in assessing response to 
therapies in clinical trials, and whether there is a need for independent central review of imaging 
results when PFS is used as an endpoint. Dodd noted that the use of PFS is an area of active 
debate, and that in general PFS does not measure clinical benefit, nor is it a surrogate for overall 
survival. A trial with PFS as a primary endpoint requires strong evidence that the treatment effect 
is large, she said—greater evidence than would be required when overall survival is the endpoint. 
Dodd pointed out that progression assessments vary by reader, with discrepancy rates in 
the timing and presence of progression typically greater than 30 percent. This has led to concern 
that there is potential for reader bias in unblinded trials due to local evaluators knowing the 
treatment assignment, prompting the requirement for blinded independent central review.  
But Dodd’s study, published in 2008, showed that treatment effects were similar when estimated 
using central review or local evaluations (Dodd et al., 2008). Two more recent reviews of cancer 
clinical trials found more than 90 percent correlation in the hazard ratios between blinded 
independent central reviews and local assessments of progression of solid tumors (Amit et al., 
2011; Zhang et al., 2013). “Given this, we have to ask ourselves, what is the value of central 
review?” Dodd said. As an alternative to central review, she suggested using overall survival as 
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an endpoint instead of PFS, but recognized that this is often not feasible. Dodd proposed that 
central review should also not be required in double-blinded studies in which the radiologists did 
not know the treatment assignment. Another alternative would be to audit for bias by doing 
blinded, independent central review on a small subset of cases. 
In July 2012, an FDA advisory committee considered this issue and all committee 
members agreed that a prospectively defined audit approach should be considered. They advised 
against complete elimination of blinded independent central review, Dodd reported. She added 
that the EMA has some guidelines that suggest it is also open to an audit approach. “Moving 
forward, we need to just make sure that any method we come up with is able to identify bias,” 
Dodd said. “An audit using central review may be the best strategy today, but technological 
advances may offer alternative solutions in the future,” she stated. “We should think about ways 
to ensure that local reviews are blinded because the true effect of a drug on PFS may be best 
estimated in a double blind trial,” Dodd concluded.  
But Sledge questioned the value of independent reviews. He noted that in one ECOG 
clinical trial, two radiologists reading the images disagreed almost half the time. “Does anyone 
seriously believe adding a third radiologist’s readings will be of statistical benefit?” he asked. 
“Why are we still even contemplating blinded independent review given that this is an 
experiment that’s been tried and failed?” Dodd responded,  
 
It’s true that the discrepancy rates are shockingly high if you just look at the discordancy 
raw numbers, but what’s most important is the hazard ratios, which are estimates of 
treatment effect. What studies show is that in spite of those high discrepancy rates, the 
hazard ratios are in general agreement. Looking at the discrepancy rates alone is not 
really the answer we’re looking for. Adding another radiologist doesn’t solve the 
problem, but if you have two radiologists’ assessments and the treatment effects as 
estimated by those reads are in general agreement, that makes us feel more comfortable 
that there wasn’t a lot of systematic bias. 
  
Pazdur added, “We have a regulatory obligation to make sure there isn’t bias. If the trial is truly 
blinded, you don’t need independent review. But most trials in oncology are unblinded because 
of the differential toxicity between the control and treatment arms of the trial, so one has to have 
some comfort that there is a true finding. That’s why we’re looking at these alternative 
mechanisms to ensure there is no bias.”  
Pazdur gave an example of a trial of a treatment for carcinoid in which the data safety 
monitoring committee recommended closure of the study for early demonstration of efficacy, 
based on the PFS rate, while another group reviewing the same study recommended it should be 
closed for futility. “That demonstrated to us that bias crept into the study,” he said, although 
Dodd added that carcinoids are particularly difficult cancers on which to assess progression. 
Dodd’s statement led Comis to suggest some studies may pose more bias than others, and should 
have a different bias-monitoring strategy imposed on them. 
Schilsky said that “if there’s any bias introduced to a study, it’s not at the level of the 
reading radiologist,” because it is uncommon for radiologists “to be aware of or to care about 
what the treatment is that’s being tested. The risk of bias comes from how the oncologist 
interprets that information that comes from those radiology reads.” But he added that in large 
clinical trials, the bias contribution of a single oncologist would be minor and wouldn’t be likely 
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to influence the outcomes. “If all the participating physicians in the trial have a systematic bias, 
then that trial was doomed from the start. It’s a bigger issue than just reading the films,” he said.  
Sherman stated that bias in “single trials [used to gain FDA approval] is the most concern 
to us because we’re making a very major decision based on a study whose findings were not 
replicated. Unblinded trials introduce more uncertainty, and simply hoping there isn’t bias isn’t 
the same thing as assessing whether or not there is.” In response to a participant who asked what 
industry can expect in this regard, Sherman answered, “The end of a phase II trial is the time to 
have that discussion about bias and monitoring with the FDA. One type of monitoring is 
appropriate for one study design, but in another situation it may not be. It’s never going to be a 
one size fits all.” Pazdur agreed, adding,  
 
We’re dealing here with a subjective endpoint that is much different than overall survival, 
so we have to make certain there is no bias. You would have to guarantee that there was 
training on the sites of radiologists, and that there wasn’t communication between the 
radiologists and the treating physicians, because as we all know a doctor may go down to 
a radiologist to read the images. Due to discussions between the physician and the 
radiologist, there can be changes in interpretations and which metastatic disease sites are 
measured, depending on if a doctor wants the patients to continue on a particular 
treatment because he thinks it’s benefiting them. 
  
Pazdur said that the FDA welcomes sponsors to suggest the least burdensome way to 
ensure there is no bias in their studies that use PFS as an endpoint. Francesco Pignatti, head of 
oncology, hematology, and diagnostics in the Safety and Efficacy Sector at the EMA, said that 
the EMA is also open to approaches for demonstrating lack of bias. “Blinding the local 
evaluation is an excellent proposal. I’m also confident that the audit approach will evolve 
quickly as soon as we gain experience on how and when to use it. We’re trying to simplify 
things, so in the training and monitoring of the local evaluation, and the firewalls between 
radiology and clinical oncology, let’s be careful that this doesn’t result in inefficiencies,” he said. 
Roychowdhury noted that some inefficiencies in clinical trials are due to excessive 
procedures instituted not only because of regulatory needs, but also because of paranoia on the 
part of sponsors about what the regulatory authorities want to see. “We cannot solve that by 
guidances, so how can we have more discussions between the regulatory agencies and the 
sponsors, especially for those on breakthrough therapies, so we can reduce the timeline of the 
trial?” he asked. Pignatti agreed that there can be excessive data collection for unimportant 
aspects due to sponsors’ lack of understanding that regulatory guidelines have flexibility and are 
not one size fits all.  
Sherman responded that as a general rule, when in doubt, sponsors should “consult with 
FDA early and often to make sure [they are] collecting what’s important.” She agreed that often 
investigators collect an excessive amount of data or the wrong type of data because they believe 
such data are needed to garner an FDA approval for the treatment being tested. “Why is there 
this compulsion to collect every piece of data and check every box? Please come talk to us and 
think about how to make sure we’re making every dollar, and more importantly, every patient, 
count in clinical trials,” she said.  
Global Regulation 
Pignatti spoke about global regulation, including European regulation of clinical trials, 
how it differs from U.S. regulation, and efforts to harmonize international regulations. He noted 
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that in Europe, the EMA is responsible for premarket evaluation of drugs as well as supervision 
of drugs once they reach the market. The European Union (EU) recently reviewed and revised its 
clinical trials legislation to take a more risk-based approach, and the EMA is trying to foster 
earlier and more continuous communications between regulators and sponsors. But he added that 
although the EMA will give advice to sponsors about trial design and conduct, that advice is 
optional and not binding; individual countries have not given the agency authority over design, 
approval, and conduct of clinical trials. 
The main divergence between EU and U.S. regulation is in the area of early approval 
mechanisms, Pignatti said. The FDA will grant accelerated approval for a treatment for a serious 
or life-threatening disease based on a surrogate endpoint likely to predict clinical benefit, with 
confirmation of benefit in postmarketing monitoring. The new agent for an accelerated approval 
has to be more effective than available therapy. 
The European Union, in contrast, will grant a conditional marketing authorization for a 
treatment that fulfills an unmet medical need for a serious, life-threatening, or orphan disease or 
in response to emergency threats. Even if the clinical data are not complete, authorization will be 
granted if researchers can show a positive benefit-risk balance, and if that benefit is confirmed 
with monitoring after the treatment has entered the market. “The critical difference is that in 
Europe, the benefit-risk must be as positive as for any other type of approval,” Pignatti 
explained. 
In 2004, the EMA and the FDA forged a confidentiality agreement to improve dialogue 
between the two agencies, recognizing that both share the same fundamental public health 
mission. This agreement has resulted in regular and ad hoc discussions and shared activities 
between the two agencies “that have been very successful,” Pignatti said. “There are few 
differences now in our general guidances. The more difficult part is when we come to applying 
them, because regulators have to make decisions in the presence of uncertainty,” he concluded. 
In situations with the most uncertainty (e.g., in the review of small, single-arm studies, 
studies done on heterogeneous populations, or early-approval applications), the two agencies can 
differ in their decisions, he noted. “In areas of very high uncertainty or situations where the 
benefit-risk balance is very close, you can continue to expect to see differences, because even 
having the best intentions and processes in place does not guarantee full harmonization,” Pignatti 
said. 
For example, the FDA revoked approval of bevacizumab for breast cancer treatment 
because new studies did not show improvement in overall survival, but the EMA found that the 
benefits of bevacizumab in combination with paclitaxel outweighed its risks and approved the 
combination (Burstein, 2011; EMA, 2010). One study found that for 42 anticancer drugs 
approved by the EMA between 1995 and 2008, there were substantial differences between EMA 
and FDA decisions. Nearly half (47 out of 100) of the indications for these drugs had differences 
in approval; for 19 indications, approval was granted only by one agency, and 28 indications 
were approved by both the EMA and FDA but with different restrictions (Trotta et al., 2011). 
Sixty-nine of the indications were approved first in the United States, although the time lag 
between FDA and EMA approvals is decreasing, Pignatti said. 
According to Pignatti, another major discrepancy between FDA and EMA oversight is 
how the two agencies view the use of PFS as an endpoint in registration trials. Although both 
agencies agree that overall survival is a more clinically relevant endpoint than PFS, the EMA 
accepts PFS if it measures a clinical benefit, whereas the FDA tends to view it as a surrogate for 
overall survival. “Even within our community and our committees, this is a hotly debated issue,” 
Copyright © National Academy of Sciences. All rights reserved.
Implementing a National Cancer Clinical Trials System for the 21st Century:  Second Workshop Summary
 
 
PREPUBLICATION COPY: UNCORRECTED PROOFS 
48
Pignatti noted. This is problematic given that PFS is increasingly being used as an endpoint; one 
study found that between 1995 and 2000, only 21 percent of pivotal confirmatory trials used PFS 
as the primary endpoint, but the rate increased to 49 percent between 2006 and 2010. “The 
different understanding of the clinical relevance of PFS is something we definitely want to work 
on,” Pignatti said. 
New Models for Regulation of Drug Development 
Eichler described the New Drug Development Paradigms (NEWDIGS), a collaborative 
effort that began at the Massachusetts Institute of Technology and includes representatives from 
drug regulators, drug companies, payers, patient organizations, and academic institutions. 
NEWDIGS’s objective is to reliably and sustainably deliver new, better, and affordable drugs to 
the right patients faster, and to counter “Pharmageddon,” as Eichler described the current 
situation. “The innovation engine, particularly in the biopharmaceutical industry, isn’t humming 
along as it should be. Everybody is a bit disgruntled and dissatisfied, whether you’re a patient, in 
pharma, a provider, a payer, or a regulator,” he said.  
NEWDIGS was designed to provide a unique, collaborative environment for innovation 
and learning that is creative and non-bureaucratic, taps the entrepreneurship and collective 
intelligence of its participants, and has a collaborative impact similar to what the SEMATECH 
collaboration had on the semiconductor industry in the 1980s.9 “NEWDIGS calls itself not just a 
‘think tank’ but also a ‘do tank.’ They want to catalyze pilot studies in real life, not just sit and 
think,” Eichler explained. NEWDIGS takes a systems approach to catalyzing change by 
exploring the co-evolution of processes, technologies, policies, and people, he added.  
NEWDIGS has developed the concept of adaptive licensing (Eichler et al., 2012) to 
counter some of the problems currently experienced with the regulation of new drugs. According 
to Eichler, these problems stem in part from the binary nature of that regulation. There is gradual 
learning about the effects of new drugs in a limited number of animals and people that occurs 
preclinically and during clinical testing. But “the next morning after that ‘magic moment’ when 
the new drug is approved, it’s out the door and anyone can have it and we have no idea what 
happens to these patients. Is that wise?” Eichler asked.  
Another problem is that some patient groups are frustrated that new drugs are not offered 
sooner to them, while some consumer advocates maintain that more needs to be known about 
drugs before they enter the market. As FDA Commissioner Margaret Hamburg has noted, it has 
been said that the FDA has just “two speeds of approvals—too fast and too slow” (Hamburg, 
2010). 
To counter both problems, NEWDIGS has proposed “doing away with the magic 
moment and creating a number of milestones where we look at the data on the drug repeatedly 
over time and align the way a drug becomes available with the growing knowledge as 
uncertainty is progressively reduced. We can broaden the access of the drug this way,” Eichler 
explained. He noted that in the current regulation scheme, during post-licensing of a drug, the 
treatment population grows rapidly but the treatment experience does not contribute to evidence 
generation. With adaptive licensing, in contrast, after initial license of the drug, the number of 
treated patients grows more slowly due to restrictions on use, and the patient experience is 
captured, contributing real-world information about the safety and effectiveness of the drug (see 
Figure 5). 
                                            
9 Sematech is a global collaboration with the objective of accelerating the commercialization of technology 
innovations into manufacturing solutions (see http://www.sematech.org/corporate/index.htm). 
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FIGURE 5 Adaptive licensing captures more of the patient experience, contributing more real-world 
information about the safety and effectiveness of drugs. 
NOTES: A = traditional licensing, B = Adaptive licensing; RCT = randomized controlled trial. 
SOURCE: Eichler presentation (February 12, 2013). 
 
Eichler explained that adaptive licensing is a prospectively planned, adaptive approach to 
the regulation of drugs that has iterative phases of evidence gathering followed by regulatory 
evaluation and license adaptation, which can specify that the drug be withdrawn from the market 
or continue to be offered to patients. Adaptive licensing seeks to maximize the positive impact of 
new drugs on public health by balancing timely access for patients with the need to provide 
evolving information on benefits and harms. “Adaptive licensing is basically the tradeoff 
between access and knowledge,” he said. 
Eichler noted that similar licensing already occurs with the FDA’s accelerated approval 
licensing and with EMA’s Conditional Marketing Authorisation, and can be aided by 
pharmacovigilance tools that detect adverse reactions to drugs. He added that to achieve the full 
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potential of adaptive licensing, licensing decisions should be aligned with coverage and 
prescribers’ decisions.  
Adaptive licensing will require not only randomized controlled trials, but also 
observational studies. Although some experts are hesitant to rely on such studies, which are 
considered lower in the hierarchy of evidence-based research, “many regulatory decisions are 
already based on case studies,” Eichler pointed out. For example, the FDA may decide to 
withdraw a drug from the market or alter its label based on adverse event reports, which are 
essentially case reports, he noted.  
Unlike clinical trials, which have strict conditions for patient participation, observational 
studies have the advantage of better detecting drug effects in the “real world,” when they are 
combined with other medications or influenced by concomitant conditions, Eichler added. He 
stressed, “We have to have the full spectrum of evidence-generation methodologies at our 
disposal, and you especially will need rapid learning systems in oncology where you probably 
have more variables than you have patients. The more information you can gather from the real 
world, the faster the learning experience will be.” The needs and potential benefits of a rapid 
learning system for cancer were described in a past NCPF workshop (IOM, 2010a). 
WRAP-UP 
After a day and a half of presentations, speakers and participants agreed that much has 
been accomplished since the publication of the IOM consensus report to improve the efficiency, 
innovation, oversight, and collaboration potential of the NCTN. But due to the rapidly changing 
nature of cancer research, challenges still remain. 
“There has been an enormous amount of change in just 2 years that has been in a very 
positive direction,” Doroshow said. Looking forward, the NCI aims to foster an NCTN “that’s 
not just for treatment, screening, and diagnosis, but for control and prevention as well,” he 
stressed. He added, “I hope as we fund our new system, we will have a very functional platform 
that allows us to screen and find the patients we need for the molecular trials that are the trials of 
the future.” Comis added that although there are still major challenges with biomarker screening, 
there is a real “opportunity to position the NCTN groups to play a critical role in the 
development of more targeted therapies.”  
Doroshow concluded that “it’s remarkable that we can, in a financially tight time, come 
together to understand where the most important science is and what critical infrastructures we 
need to allow that science to go forward. We have done our job to modernize the system.” 
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ACRONYMS 
 
ACOSOG American College of Surgeons Oncology Group 
ACRIN American College of Radiology Imaging Network 
AE adverse event 
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification in Sequencing Trial
ALK anaplastic lymphoma kinase 
AML Acute Myeloid Leukemia 
ASCO American Society of Clinical Oncology 
  
BRAF human homolog B of v-raf (Rapidly Accelerated Fibrosarcoma viral 
oncogene) 
  
CALGB Cancer and Leukemia Group B 
CCOP Community Clinical Oncology Program 
CDER Center for Drug Evaluation and Research 
CDMS Common IT Data Management System 
CIRB Central Institutional Review Board 
CLIA Clinical Laboratory Improvement Amendments 
CMS Centers for Medicare & Medicaid Services 
CRADA Cooperative Research and Development Agreements 
CRUK Cancer Research UK 
CSG Clinical Studies Group 
CT computed tomography 
CTAC Clinical Trials and Translational Research Advisory Group 
CTEP Cancer Therapy Evaluation Program 
CTU Clinical Trials Unit 
  
DNA deoxyribonucleic acid 
  
ECOG Eastern Cooperative Oncology Group 
EGFR epidermal growth factor receptor 
EMA European Medicines Agency 
  
FDA Food and Drug Administration 
FLT3 fms-like tyrosine kinase 3 (fms is the receptor for macrophage colony 
stimulating factor) 
  
GOG Gynecologic Oncology Group 
  
HER2 human epidermal growth factor receptor 2 
  
IDE Investigational Device Exemption 
IND Investigational New Drug 
IOM Institute of Medicine 
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IP intellectual property 
IRB institutional review board 
IRF independent radiology facility 
IT information technology 
  
KRAS Kirsten rat sarcoma oncogene 
  
NCCCP NCI Community Cancer Centers Program 
NCCTG North Central Cancer Treatment Group 
NCI National Cancer Institute 
NCORP NCI Community Oncology Research Program 
NCPF National Cancer Policy Forum 
NCRI National Cancer Research Institute 
NCRN National Cancer Research Network 
NCTN National Clinical Trial Network 
NEWDIGS New Drug Development Paradigms 
NGS next generation sequencing 
NHS National Health Service 
NIH National Institutes of Health 
NIHR National Institute of Health Research 
NSABP National Surgical Adjuvant Breast and Bowel Project 
  
OEWG Operational Efficiency Working Group 
  
PET positron emission tomography 
PFS progression-free survival 
PTEN phosphatase and tensin homolog 
  
RATIFY Randomized AML Trial In FLT3 in <60 Year Olds 
RDC remote data capture 
RFA request for application 
RTOG Radiation Therapy Oncology Group 
  
SEMATECH Semiconductor Manufacturing Technology 
SOP standard operating procedure 
SSC Scientific Steering Committee 
START Standard Terms of Agreement for Research Trials 
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A 
 
Workshop Statement of Task and Agenda 
 
 
Implementing a National Cancer Clinical Trials System  
for the 21st Century, Workshop #2 
 
Hosted by the American Society of Clinical Oncology and  
the Institute of Medicine’s National Cancer Policy Forum  
 
Statement of Task 
 
An ad hoc committee will plan and conduct a public workshop to identify and examine 
ongoing activities to implement the recommendations put forth in the Institute of Medicine 
(IOM) consensus report A National Cancer Clinical Trials System for the 21st Century: 
Reinvigorating the NCI Cooperative Group Program. The first workshop (to be held in early 
2011) would invite all stakeholders charged with making changes to the system (e.g., National 
Cancer Institute [NCI], Food and Drug Administration [FDA], Office for Human Research 
Protections [OHRP], Centers for Medicare & Medicaid Services [CMS], NCI Cooperative Group 
Chairs, drug/biotech/device industry, patient advocates, investigators at academic and 
community sites, and private payers) to discuss what changes they plan to implement in response 
to the IOM recommendations. The second workshop (to be held in 2013) would reconvene the 
stakeholders to discuss progress made to date and to identify additional actions to take. 
Individually authored summaries of the workshops will subsequently be prepared by a 
designated rapporteur. 
 
February 11, 2013 
 
7:30 am Registration 
 
8:15 am Welcome from the IOM’s National Cancer Policy Forum  
 John Mendelsohn, MD Anderson Cancer Center, 
Chair, National Cancer Policy Forum  
 
Introduction to Workshop  
 Monica Bertagnolli, Alliance for Clinical Trials in Oncology and  
Dana-Farber Cancer Institute (DFCI), Workshop Planning Committee Chair 
 
8:25 am  
 
Session 1: Updates from NCI and the National Clinical Trials Network (NCTN) 
Components: Progress To Date 
Moderator: James Doroshow, NCI 
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NCI Updates  
 James Doroshow, NCI Division of Cancer Treatment and Diagnosis  
 
Updates from the Cooperative Groups 
 Robert Comis, ECOG-ACRIN Cancer Research Group 
 
Updates on the Community Clinical Oncology Programs (CCOPs)/NCI Community 
Cancer Centers Program/NCI Community Oncology Research Program (NCORP) 
 Worta McCaskill-Stevens, NCI Division of Cancer Prevention 
 
Panel Discussion 
Speakers above plus representatives of community practices in the NCORP: 
 Stephen Grubbs, Helen F. Graham Cancer Center and Christiana Care CCOP 
 Robin Zon, Michiana Hematology-Oncology, and Northern Indiana Cancer 
Research Consortium CCOP 
 
10:00 am Break 
 
10:15 am Session 2: Funding for Cancer Clinical Trials 
Moderator: John Mendelsohn, MD Anderson Cancer Center 
 
Metrics on Technical Risks, Clinical Development Times and Approval Times for 
Cancer Drugs 
 Joseph DiMasi, Tufts Center for the Study of Drug Development  
 
Funding Clinical Trials in the Academic and Community Research Environment 
 Marc Sabatine, Thrombolysis in Myocardial Infarction Study Group 
  
Foundation Perspective  
 Margaret Anderson, FasterCures 
 
Panel Discussion 
 
11:45 am Lunch Break 
 
12:30 pm Session 3: Prioritization of Cancer Trials in a Changing Environment 
Moderator: George Sledge, Stanford University School of Medicine 
 
Status Report from the CTAC Strategic Planning Subcommittee 
 George Sledge, Stanford University School of Medicine  
 Robert Diasio, Mayo Clinic Cancer Center 
 
An International Perspective from the UK Network on Prioritization of Trials:  
 Richard Kaplan, UK National Cancer Research Network &  
Medical Research Council  
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Panel Discussion 
 
1:45 pm Session 4: The NCTN as a Platform to Implement Precision Medicine 
Moderator: Barbara Conley, NCI Division of Cancer Treatment and Diagnosis 
 
Resources Needed for a Trial Employing Genomic Profiling for Eligibility 
 Levi Garraway, DFCI 
 
Information from “Exceptional Responders” and the Implementation of Basket 
Trials  
 David Solit, Memorial Sloan-Kettering Cancer Center  
 
Challenges in Real-World Implementation of Genomic Profiling for Eligibility in 
Broad, National Clinical Trials 
 Vincent Miller, Foundation Medicine  
 
Investigational Device Exemption Requirements for Diagnostic Tests Used in 
Clinical Trials 
 John Jessup, Diagnostics Evaluation Branch, NCI Division of Cancer 
Treatment and Diagnosis  
 
Panel Discussion 
 
3:45 pm Break 
 
4:00 pm  
 
Panel Discussion 
Moderator: Michael Caligiuri, Ohio State University Comprehensive Cancer Center 
 
Panelists:  
Cooperative Group Chairs 
 Charles Blanke, SWOG  
 Robert Comis, ECOG-ACRIN  
 Peter Adamson, Children’s Oncology Group  
 Walter Curran, NRG Oncology Group  
NCI 
 James Doroshow, NCI Division of Cancer Treatment and Diagnosis 
FDA 
 Richard Pazdur, FDA Office of Hematology and Oncology Products 
Advocates  
 Nancy Roach, Fight Colorectal Cancer  
 Patrick Gavin, Patrick Gavin R.Ph. Consulting LLC  
 
5:30 pm Wrap Up Day 1 and Adjourn 
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February 12, 2013 
 
7:30 am Registration 
 
8:00 am  
 
Session 5: Accelerating Innovation Through Effective Partnerships  
Moderator: Monica Bertagnolli, Alliance for Clinical Trials in Oncology and DFCI 
 
Comprehensive Cancer Center Perspectives  
 Edward Benz, DFCI 
 
Industry Perspective 
 Renaud Capdeville, Novartis Oncology 
 
International Perspective:  NEWDIGS Initiative,  Massachusetts Institute of 
Technology Center for Biomedical Innovation 
 Hans-Georg Eichler, European Medicines Agency (EMA) 
 
Accelerating Innovation in Statistical Design 
 Lisa McShane, NCI Division of Cancer Treatment and Diagnosis 
 
Partnering with Advocates 
 Patrick Gavin, Patrick Gavin R.Ph. Consulting LLC  
 
Panel Discussion 
 
10:45 am Break  
 
11:00 am Session 6: Regulatory Issues  
Moderator: Richard L. Schilsky, American Society of Clinical Oncology (ASCO) 
 
Optimizing Safety Data Collection in Cancer Clinical Trials 
 Richard L. Schilsky, ASCO 
 
FDA Perspective on Data Quality Issues 
 Rachel Sherman, FDA Office of Medical Policy 
 
The Role of the Cancer Therapy Evaluation Program/NCI in Registration Trials 
 Jeffrey Abrams, NCI Division of Cancer Treatment and Diagnosis 
 
FDA/NCI Collaboration—Independent Radiologic Review 
 Lori Dodd, NCI Biostatistics Research Branch  
 
Pharmaceutical Industry 
 Sandra Horning, Genentech  
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EMA-FDA  Harmonization 
 Francesco Pignatti, EMA 
 
Panel Discussion 
Speakers plus: 
 Robert Iannone, Merck Research Laboratories 
 Debasish Roychowdhury, Sanofi Oncology 
 
1:45 pm Workshop Wrap-Up 
 Monica Bertagnolli, Alliance for Clinical Trials in Oncology and DFCI 
 
2:00 pm Adjourn 
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